WO2022169798A2 - Substituted pyrrolopyrimidine and pyrazolopyrimidine as bruton's tyrosine kinase (btk) degraders - Google Patents

Substituted pyrrolopyrimidine and pyrazolopyrimidine as bruton's tyrosine kinase (btk) degraders Download PDF

Info

Publication number
WO2022169798A2
WO2022169798A2 PCT/US2022/014830 US2022014830W WO2022169798A2 WO 2022169798 A2 WO2022169798 A2 WO 2022169798A2 US 2022014830 W US2022014830 W US 2022014830W WO 2022169798 A2 WO2022169798 A2 WO 2022169798A2
Authority
WO
WIPO (PCT)
Prior art keywords
pyrimidin
amino
piperazin
dioxopiperidin
piperidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2022/014830
Other languages
English (en)
French (fr)
Other versions
WO2022169798A3 (en
Inventor
Yimin Qian
Wei He
Robert Luo
Jie Su
Hui Zhang
Ke Liu
Jie Fan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Accutar Biotechnology Inc
Original Assignee
Accutar Biotechnology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Accutar Biotechnology Inc filed Critical Accutar Biotechnology Inc
Priority to US18/263,656 priority Critical patent/US20240132502A1/en
Priority to KR1020237029298A priority patent/KR20230142539A/ko
Priority to MX2023008865A priority patent/MX2023008865A/es
Priority to CA3209082A priority patent/CA3209082A1/en
Priority to CN202280022626.5A priority patent/CN117042769A/zh
Priority to JP2023546433A priority patent/JP2024505558A/ja
Publication of WO2022169798A2 publication Critical patent/WO2022169798A2/en
Publication of WO2022169798A3 publication Critical patent/WO2022169798A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Definitions

  • the present invention relates to compounds that modulate Bruton’s tyrosine kinase (BTK).
  • the present invention relates to compounds that have a degrading effect on BTK, pharmaceutical compositions comprising the compounds and methods of use therefor.
  • B-cell receptor can lead to a range of biological outputs depending upon, in part, the developmental stage of the B-cell. Faulty signaling through the BCR can cause dysregulation of the B-cell function and/or the formation of auto-antibodies which may lead to the auto-immune and/or inflammatory diseases. Therapeutics, such as Rituxan, which deplete B-cells are effective in the treatment of inflammatory diseases such as rheumatoid arthritis.
  • BTK is a Tec family non-receptor protein kinase, expressed in most hematopoietic cells such as B cells, mast cells, and macrophages but not in T cells, natural killer cells, and plasma cells.
  • BTK is a crucial part of the BCR and FcR signaling pathway, and the targeted inhibition of BTK is a novel approach for treating many different human diseases such as B-cell malignancies, autoimmune disease, and inflammatory disorders.
  • diseases such as B-cell malignancies, autoimmune disease, and inflammatory disorders.
  • Uckun Fatih M. et al, Anti-Cancer Agents in Med Chem.7(6):624-632 (2007); Shinohara et al, Cell 132(5):794-806 (2008); Pan, Z., Drug News & Perspectives, 21(7):357-362 (2008); Gilfillan et al, Immuno.
  • BTK plays a role in the development and activation of B cells and has been implicated in multiple signaling pathways across a wide range of immune-mediated diseases.
  • BTK activity has been implicated in the pathogenesis of several disorders and conditions, such as B cell-related hematological cancers (e.g., non-Hodgkin lymphoma and B cell chronic lymphocytic leukemia) and autoimmune diseases (e.g., rheumatoid arthritis, Sjogren’s syndrome, pemphigus, inflammatory bowel disease, lupus, and asthma).
  • B cell-related hematological cancers e.g., non-Hodgkin lymphoma and B cell chronic lymphocytic leukemia
  • autoimmune diseases e.g., rheumatoid arthritis, Sjogren’s syndrome, pemphigus, inflammatory bowel disease, lupus, and asthma.
  • the present disclosure is directed to a compound of Formula (I), or a tautomer, stereoisomer or a mixture of stereoisomers, or a pharmaceutically acceptable salt, or hydrate, or deuterated derivative thereof: R 3 wherein: X is CH or N; Y is CH or N; A is chosen from -C(O)-, -SO 2 -, -S(O)-, -O-, -S-, -NH-, -N(C 1 -C 5 alkyl)-, and -C(O)NH(C 1 - C 5 alkyl)-; R 1 is chosen from H, C 1 -C 3 alkyl, C 1 -C 3 haloalkyl, dialkylamino group, amino group, -CN, hydroxyl, C 1 -C 4 alkoxy, and halogen; each R 2 and R 3 is independently chosen from H, halogen, -CN
  • the compound of Formula (I) may be a compound of Formula (IA): .
  • the compound of Formula (I) may be a compound of Formula (IB): .
  • A is -O- or -C(O)-NH-CH 2 -.
  • R 1 is chosen from H, C 1 -C 3 alkyl, C 1 -C 3 haloalkyl, and halogen.
  • R 2 and R 3 are each independently chosen from H, -OCD 3 , -CD 3 , halogen, C 1 -C 4 alkyl, and C 1 -C 4 alkoxy.
  • R 4 is chosen from H, halogen, -CN, and C 1 -C 4 haloalkyl.
  • R 5 is chosen from H, halogen, deuterated C 1 -C 5 alkoxy, and C 1 - C 5 alkoxy.
  • the compound of Formula (I) e.g. Formula (IA), Formula (IB)
  • the compound of Formula (I) may encompass both racemic isomers and enantiomeric isomers.
  • a method of treating a condition which is modulated by Bruton’s tyrosine kinase (BTK) in a subject in need thereof comprising administering to the subject a compound of Formula (I) (e.g. Formula (IA), Formula (IB)) or pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof.
  • the pharmaceutical composition of the present disclosure may be for use in (or in the manufacture of medicaments for) the treatment of cancer, immunological disease, autoimmune diseases, and inflammatory diseases in the subject in need thereof.
  • a therapeutically effective amount of a pharmaceutical composition of the present disclosure may be administered to a subject suffering from a condition modulated by BTK.
  • the condition modulated by BTK is chosen from cancer, immunological disease, autoimmune diseases, and inflammatory disorders.
  • the condition is chosen from B-cell malignancy, B-cell lymphoma, diffuse large B cell lymphoma, chronic lymphocyte leukemia, non-Hodgkin lymphoma, mantle cell lymphoma, follicular lymphoma, hairy cell leukemia B-cell non-Hodgkin lymphoma, Waldenström’s macroglobulinemia, multiple myeloma, bone cancer, bone metastasis, arthritis, multiple sclerosis osteoporosis, irritable bowel syndrome, inflammatory bowel disease, Crohn's disease, lupus, Sjogren’s syndrome, and disorders associated with renal transplant.
  • FIG. 1 illustrates the BTK degradative activity of compounds 13, 25, 34, 42, 48, 49, 51, and 78 in a RAMOS cell line 6 hours after administration.
  • Figure 2 illustrates the BTK degradative activity of compounds 53, 54, 93, and 96 in a RAMOS cell line 6 hours after administration.
  • DETAILED DESCRIPTION OF THE DISCLOSURE Definitions [019] A dash (“-”) that is not between two letters or symbols is used to indicate a point of attachment for a substituent. For example, -CN is attached through the carbon atom.
  • -CN is attached through the carbon atom.
  • C 1 -C 6 alkyl is intended to encompass C 1 , C 2 , C 3 , C 4 , C 5 , C 6 , C 1-6 , C 1-5 , C 1-4 , C 1-3 , C 1-2 , C 2-6 , C 2-5 , C 2-4 , C 2-3 , C 3-6 , C 3-5 , C 3-4 , C 4-6 , C 4-5 , and C 5-6 alkyl.
  • acyl refers to R-C(O)- groups such as, but not limited to, (alkyl)-C(O)-, (alkenyl)-C(O)-, (alkynyl)-C(O)-, (aryl)-C(O)-, (cycloalkyl)-C(O)-, (heteroaryl)-C(O)-, and (heterocyclyl)-C(O)-, wherein the group is attached to the parent molecular structure through the carbonyl functionality.
  • acyl radical which refers to the total number of chain or ring atoms of the, for example, alkyl, alkenyl, alkynyl, aryl, cycloalkyl, or heteroaryl, portion plus the carbonyl carbon of acyl.
  • a C4-acyl has three other ring or chain atoms plus carbonyl.
  • alkenyl refers to an unsaturated straight or branched hydrocarbon having at least one carbon-carbon double bond, such as a straight or branched group of 2-8 carbon atoms, referred to herein as (C 2 -C 8 )alkenyl.
  • alkenyl groups include, but are not limited to, vinyl, allyl, butenyl, pentenyl, hexenyl, butadienyl, pentadienyl, hexadienyl, 2-ethylhexenyl, 2-propyl- 2-butenyl, and 4-(2-methyl-3-butene)-pentenyl.
  • alkyl refers to a saturated straight or branched hydrocarbon, such as a straight or branched group of 1-8 carbon atoms, referred to herein as C 1 -8 alkyl.
  • Exemplary alkyl groups include, but are not limited to, methyl, ethyl, propyl, isopropyl, 2-methyl-1-propyl, 2-methyl-2- propyl, 2-methyl-1-butyl, 3 methyl-1-butyl, 2-methyl-3-butyl, 2,2-dimethyl-1-propyl, 2-methyl-1-pentyl, 3 methyl-1-pentyl, 4-methyl-1-pentyl, 2-methyl-2-pentyl, 3-methyl-2-pentyl, 4 methyl-2-pentyl, 2,2- dimethyl-1-butyl, 3,3-dimethyl-1-butyl, 2-ethyl-1-butyl, butyl, isobutyl, t-butyl, pentyl, isopentyl, neopentyl, hexyl, heptyl, and octyl.
  • alkyl is a straight-chain hydrocarbon. In some embodiments, “alkyl” is a branched hydrocarbon.
  • alkoxy means a straight or branched chain saturated hydrocarbon containing 1-12 carbon atoms containing a terminal “O” in the chain, e.g., -O(alkyl). Examples of alkoxy groups include, without limitation, methoxy, ethoxy, propoxy, butoxy, t-butoxy, or pentoxy groups.
  • alkylene as used herein referes to a divalent alkyl radical.
  • C 1 -10 alkylene include, but are not limited to, methylene, ethylene, n-propylene, iso- propylene, n-butylene, sec-butylene, iso-butylene, tert-butylene, n-pentylene, isopentylene, neopentylene, n-hexylene, 3-methylhexylene, 2,2-dimethylpentylene, 2,3-dimethylpentylene, n-heptylene, n-octylene, n- nonylene and n-decylene.
  • alkynyl refers to an unsaturated straight or branched hydrocarbon having at least one carbon-carbon triple bond, such as a straight or branched group of 2-8 carbon atoms, referred to herein as (C 2 -C8)alkynyl.
  • exemplary alkynyl groups include, but are not limited to, ethynyl, propynyl, butynyl, pentynyl, hexynyl, methylpropynyl, 4-methyl-1-butynyl, 4-propyl-2- pentynyl, and 4-butyl-2-hexynyl.
  • aryl refers to a mono-, bi-, or other multi carbocyclic, aromatic ring system with 5 to 14 ring atoms.
  • the aryl group can optionally be fused to one or more rings selected from aryls, cycloalkyls, heteroaryls, and heterocyclyls.
  • aryl groups of this present disclosure can be substituted with groups selected from alkoxy, aryloxy, alkyl, alkenyl, alkynyl, amide, amino, aryl, arylalkyl, carbamate, carboxy, cyano, cycloalkyl, ester, ether, formyl, halogen, haloalkyl, heteroaryl, heterocyclyl, hydroxyl, ketone, nitro, phosphate, sulfide, sulfinyl, sulfonyl, sulfonic acid, sulfonamide, and thioketone.
  • Exemplary aryl groups include, but are not limited to, phenyl, tolyl, anthracenyl, fluorenyl, indenyl, azulenyl, and naphthyl, as well as benzo-fused carbocyclic moieties such as 5,6,7,8- tetrahydronaphthyl.
  • Exemplary aryl groups also include but are not limited to a monocyclic aromatic ring system, wherein the ring comprises 6 carbon atoms, referred to herein as “C 6 -aryl.” [028]
  • the term “cyano” as used herein refers to -CN.
  • cycloalkyl refers to a saturated or unsaturated cyclic, bicyclic, or bridged bicyclic hydrocarbon group of 3-16 carbons, or 3-8 carbons, referred to herein as “(C 3 -C 8 )cycloalkyl,” derived from a cycloalkane.
  • exemplary cycloalkyl groups include, but are not limited to, cyclohexanes, cyclohexenes, cyclopentanes, and cyclopentenes.
  • Cycloalkyl groups may be substituted with alkoxy, aryloxy, alkyl, alkenyl, alkynyl, amide, amino, aryl, arylalkyl, carbamate, carboxy, cyano, cycloalkyl, ester, ether, formyl, halogen, haloalkyl, heteroaryl, heterocyclyl, hydroxyl, ketone, nitro, phosphate, sulfide, sulfinyl, sulfonyl, sulfonic acid, sulfonamide and thioketone.
  • Cycloalkyl groups can be fused to other cycloalkyl (saturated or partially unsaturated), aryl, or heterocyclyl groups, to form a bicycle, tetracycle, etc.
  • the term “cycloalkyl” also includes bridged and spiro-fused cyclic structures which may or may not contain heteroatoms.
  • halo or “halogen” as used herein refer to -F, -Cl, -Br, and/or -I.
  • Haloalkyl means an alkyl group substituted with one or more halogens.
  • haloalkyl groups include, but are not limited to, trifluoromethyl, difluoromethyl, pentafluoroethyl, trichloromethyl, etc.
  • heteroaryl refers to a mono-, bi-, or multi-cyclic, aromatic ring system containing one or more heteroatoms, for example 13 heteroatoms, such as nitrogen, oxygen, and sulfur.
  • Heteroaryls can be substituted with one or more substituents including alkoxy, aryloxy, alkyl, alkenyl, alkynyl, amide, amino, aryl, arylalkyl, carbamate, carboxy, cyano, cycloalkyl, ester, ether, formyl, halogen, haloalkyl, heteroaryl, heterocyclyl, hydroxyl, ketone, nitro, phosphate, sulfide, sulfinyl, sulfonyl, sulfonic acid, sulfonamide and thioketone. Heteroaryls can also be fused to non-aromatic rings.
  • heteroaryl groups include, but are not limited to, a monocyclic aromatic ring, wherein the ring comprises 2-5 carbon atoms and 1-3 heteroatoms, referred to herein as “(C 2 -C 5 )heteroaryl.”
  • Illustrative examples of heteroaryl groups include, but are not limited to, pyridinyl, pyridazinyl, pyrimidyl, pyrazyl, triazinyl, pyrrolyl, pyrazolyl, imidazolyl, (1,2,3)- and (1,2,4)-triazolyl, pyrazinyl, pyrimidilyl, tetrazolyl, furyl, thienyl, isoxazolyl, thiazolyl, furyl, phenyl, isoxazolyl, and oxazolyl.
  • heteroaryl groups also include, but are not limited to, a bicyclic aromatic ring, wherein the ring comprises 5-14 carbon atoms and 1-3 heteroatoms, referred to herein as “(C 5 -C14)heteroaryl.”
  • Representative examples of heteroaryl include, but not limited to, indazolyl, indolyl, azaindolyl, indolinyl, benzotriazolyl, benzoxadiazolyl, imidazolyl, cinnolinyl, imidazopyridyl, pyrazolopyridyl, pyrrolopyridyl, quinolinyl, isoquinolinyl, quinazolinyl, quinazolinonyl, indolinonyl, isoindolinonyl, tetrahydronaphthyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, and the like.
  • heterocycle refers to a saturated or unsaturated 3- to 18-membered ring containing one, two, three, or four heteroatoms independently selected from nitrogen, oxygen, phosphorus, and sulfur.
  • Heterocycles can be aromatic (heteroaryls) or non-aromatic.
  • Heterocycles can be substituted with one or more substituents including alkoxy, aryloxy, alkyl, alkenyl, alkynyl, amide, amino, aryl, arylalkyl, carbamate, carboxy, cyano, cycloalkyl, ester, ether, formyl, halogen, haloalkyl, heteroaryl, heterocyclyl, hydroxyl, ketone, nitro, phosphate, sulfide, sulfinyl, sulfonyl, sulfonic acid, sulfonamide and thioketone.
  • substituents including alkoxy, aryloxy, alkyl, alkenyl, alkynyl, amide, amino, aryl, arylalkyl, carbamate, carboxy, cyano, cycloalkyl, ester, ether, formyl, halogen, haloalkyl, heteroaryl, heterocycly
  • Heterocycles also include bicyclic, tricyclic, and tetracyclic groups in which any of the above heterocyclic rings is fused to one or two rings independently selected from aryls, cycloalkyls, and heterocycles.
  • Exemplary heterocycles include acridinyl, benzimidazolyl, benzofuryl, benzothiazolyl, benzothienyl, benzoxazolyl, biotinyl, cinnolinyl, dihydrofuryl, dihydroindolyl, dihydropyranyl, dihydrothienyl, dithiazolyl, furyl, homopiperidinyl, imidazolidinyl, imidazolinyl, imidazolyl, indolyl, isoquinolyl, isothiazolidinyl, isothiazolyl, isoxazolidinyl, isoxazolyl, morpholinyl, oxadiazolyl, o
  • hydroxy and “hydroxyl” as used herein refer to -OH.
  • “Spirocycloalkyl” or “spirocyclyl” means carbogenic bicyclic ring systems with both rings connected through a single atom. The rings can be different in size and nature, or identical in size and nature. Examples include spiropentane, spriohexane, spiroheptane, spirooctane, spirononane, or spirodecane. One or both of the rings in a spirocycle can be fused to another ring carbocyclic, heterocyclic, aromatic, or heteroaromatic ring.
  • a (C 3-12 )spirocycloalkyl is a spirocycle containing between 3 and 12 carbon atoms.
  • “Spiroheterocycloalkyl” or “spiroheterocyclyl” means a spirocycle wherein at least one of the rings is a heterocycle one or more of the carbon atoms can be substituted with a heteroatom (e.g., one or more of the carbon atoms can be substituted with a heteroatom in at least one of the rings).
  • One or both of the rings in a spiroheterocycle can be fused to another ring carbocyclic, heterocyclic, aromatic, or heteroaromatic ring.
  • “Isomers” means compounds having the same number and kind of atoms, and hence the same molecular weight, but differing with respect to the arrangement or configuration of the atoms in space.
  • “Stereoisomer” or “optical isomer” mean a stable isomer that has at least one chiral atom or restricted rotation giving rise to perpendicular dissymmetric planes (e.g., certain biphenyls, allenes, and spiro compounds) and can rotate plane-polarized light. Because asymmetric centers and other chemical structure exist in the compounds of the disclosure which may give rise to stereoisomerism, the disclosure contemplates stereoisomers and mixtures thereof.
  • the compounds of the disclosure and their salts include asymmetric carbon atoms and may therefore exist as single stereoisomers, racemates, and as mixtures of enantiomers and diastereomers. Typically, such compounds will be prepared as a racemic mixture. If desired, however, such compounds can be prepared or isolated as pure stereoisomers, i.e., as individual enantiomers or diastereomers, or as stereoisomer-enriched mixtures.
  • individual stereoisomers of compounds are prepared by synthesis from optically active starting materials containing the desired chiral centers or by preparation of mixtures of enantiomeric products followed by separation or resolution, such as conversion to a mixture of diastereomers followed by separation or recrystallization, chromatographic techniques, use of chiral resolving agents, or direct separation of the enantiomers on chiral chromatographic columns.
  • Starting compounds of particular stereochemistry are either commercially available or are made by the methods described below and resolved by techniques well-known in the art. [039] It is well-known in the art that the biological and pharmacological activity of a compound is sensitive to the stereochemistry of the compound.
  • enantiomers often exhibit strikingly different biological activity including differences in pharmacokinetic properties, including metabolism, protein binding, and the like, and pharmacological properties, including the type of activity displayed, the degree of activity, toxicity, and the like.
  • one enantiomer may be more active or may exhibit beneficial effects when enriched relative to the other enantiomer or when separated from the other enantiomer.
  • one skilled in the art would know how to separate, enrich, or selectively prepare the enantiomers of the compounds of the disclosure from this disclosure and the knowledge of the prior art.
  • racemic form of drug may be used, it is often less effective than administering an equal amount of enantiomerically pure drug; indeed, in some cases, one enantiomer may be pharmacologically inactive and would merely serve as a simple diluent.
  • ibuprofen had been previously administered as a racemate, it has been shown that only the S-isomer of ibuprofen is effective as an anti-inflammatory agent (in the case of ibuprofen, however, although the R- isomer is inactive, it is converted in vivo to the S-isomer, thus, the rapidity of action of the racemic form of the drug is less than that of the pure S-isomer).
  • the pharmacological activities of enantiomers may have distinct biological activity.
  • S-penicillamine is a therapeutic agent for chronic arthritis, while R-penicillamine is toxic.
  • R-penicillamine is toxic.
  • some purified enantiomers have advantages over the racemates, as it has been reported that purified individual isomers have faster transdermal penetration rates compared to the racemic mixture. See U.S. Pat. Nos.5,114,946 and 4,818,541.
  • the compound is a racemic mixture of (S)- and (R)-isomers.
  • provided herein is a mixture of compounds wherein individual compounds of the mixture exist predominately in an (S)- or (R)-isomeric configuration.
  • the compound mixture has an (S)-enantiomeric excess of greater than about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, about 99%, about 99.5%, or more.
  • the compound mixture has an (S)-enantiomeric excess of greater than about 55% to about 99.5%, greater than about 60% to about 99.5%, greater than about 65% to about 99.5%, greater than about 70% to about 99.5%, greater than about 75% to about 99.5%, greater than about 80% to about 99.5%, greater than about 85% to about 99.5%, greater than about 90% to about 99.5%, greater than about 95% to about 99.5%, greater than about 96% to about 99.5%, greater than about 97% to about 99.5%, greater than about 98% to greater than about 99.5%, greater than about 99% to about 99.5%, or more.
  • the compound mixture has an (R)-enantiomeric purity of greater than about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, about 99%, about 99.5% or more.
  • the compound mixture has an (R)-enantiomeric excess of greater than about 55% to about 99.5%, greater than about 60% to about 99.5%, greater than about 65% to about 99.5%, greater than about 70% to about 99.5%, greater than about 75% to about 99.5%, greater than about 80% to about 99.5%, greater than about 85% to about 99.5%, greater than about 90% to about 99.5%, greater than about 95% to about 99.5%, greater than about 96% to about 99.5%, greater than about 97% to about 99.5%, greater than about 98% to greater than about 99.5%, greater than about 99% to about 99.5% or more.
  • Individual stereoisomers of compounds of the present disclosure can be prepared synthetically from commercially available starting materials that contain asymmetric or stereogenic centers, or by preparation of racemic mixtures followed by resolution methods well known to those of ordinary skill in the art. These methods of resolution are exemplified by: (1) attachment of a mixture of enantiomers to a chiral auxiliary, separation of the resulting mixture of diastereomers by recrystallization or chromatography and liberation of the optically pure product from the auxiliary; (2) salt formation employing an optically active resolving agent; or (3) direct separation of the mixture of optical enantiomers on chiral chromatographic columns.
  • Stereoisomeric mixtures can also be resolved into their component stereoisomers by well-known methods, such as chiral-phase gas chromatography, chiral-phase high performance liquid chromatography, crystallizing the compound as a chiral salt complex, or crystallizing the compound in a chiral solvent.
  • Stereoisomers can also be obtained from stereomerically- pure intermediates, reagents, and catalysts by well-known asymmetric synthetic methods. [043]
  • one enantiomer is pharmacologically more active, less toxic, or has a preferred disposition in the body than the other enantiomer, it would be therapeutically more beneficial to administer that enantiomer preferentially.
  • compositions refers to a composition comprising at least one compound as disclosed herein formulated together with one or more pharmaceutically acceptable carriers.
  • prodrugs as used herein represents those prodrugs of the compounds of the present disclosure that are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response, commensurate with a reasonable benefit / risk ratio, and effective for their intended use, as well as the zwitterionic forms, where possible, of the compounds of the present disclosure.
  • a discussion is provided in Higuchi et al., “Prodrugs as Novel Delivery Systems,” ACS Symposium Series, Vol.14, and in Roche, E.B., ed. Bioreversible Carriers in Drug Design, American Pharmaceutical Association and Pergamon Press, 1987, both of which are incorporated herein by reference.
  • salts refers to salts of acidic or basic groups that may be present in compounds used in the present compositions.
  • Compounds included in the present compositions that are basic in nature are capable of forming a wide variety of salts with various inorganic and organic acids.
  • the acids that may be used to prepare pharmaceutically acceptable acid addition salts of such basic compounds are those that form non-toxic acid addition salts, i.e., salts containing pharmacologically acceptable anions, including but not limited to sulfate, citrate, matate, acetate, oxalate, chloride, bromide, iodide, nitrate, sulfate, bisulfate, phosphate, acid phosphate, isonicotinate, acetate, lactate, salicylate, citrate, tartrate, oleate, tannate, pantothenate, bitartrate, ascorbate, succinate, maleate, gentisinate, fumarate, gluconate, glucaronate, saccharate, formate, benzoate, glutamate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate and pamoate (i
  • Compounds included in the present compositions that include an amino moiety may form pharmaceutically acceptable salts with various amino acids, in addition to the acids mentioned above.
  • Compounds included in the present compositions, that are acidic in nature are capable of forming base salts with various pharmacologically acceptable cations.
  • Examples of such salts include alkali metal or alkaline earth metal salts and, particularly, calcium, magnesium, sodium, lithium, zinc, potassium, and iron salts.
  • the compounds of the disclosure may contain one or more chiral centers and/or double bonds and, therefore, exist as stereoisomers, such as geometric isomers, enantiomers or diastereomers.
  • stereoisomers when used herein consist of all geometric isomers, enantiomers or diastereomers.
  • Stereoisomers include enantiomers and diastereomers. Mixtures of enantiomers or diastereomers may be designated “( ⁇ )” in nomenclature, but the skilled artisan will recognize that a structure may denote a chiral center implicitly. In some embodiments, an enantiomer or stereoisomer may be provided substantially free of the corresponding enantiomer.
  • cancer refers to diseases, disorders, and conditions that involve abnormal cell growth with the potential to invade or spread to other parts of the body.
  • Exemplary cancers include, but are not limited to, breast cancer, lung cancer, ovarian cancer, endometrial cancer, prostate cancer, and esophageal cancer.
  • the term “subject” refers to an animal. Typically, the animal is a mammal. A subject also refers to for example, primates (e.g., humans, male or female), cows, sheep, goats, horses, dogs, cats, rabbits, rats, mice, fish, birds and the like. In certain embodiments, the subject is a primate. In yet other embodiments, the subject is a human.
  • the term “inhibit,” “inhibition,” or “inhibiting” refers to the reduction or suppression of a given condition, symptom, or disorder, or disease, or a significant decrease in the baseline activity of a biological activity or process.
  • the term “treat,” “treating,” or “treatment” of any disease or disorder refers in one embodiment, to ameliorating the disease or disorder (i.e., slowing or arresting or reducing the development of the disease or at least one of the clinical symptoms thereof). In another embodiment “treat,” “treating,” or “treatment” refers to alleviating or ameliorating at least one physical parameter including those which may not be discernible by the patient.
  • “treat,” “treating,” or “treatment” refers to modulating the disease or disorder, either physically (e.g., through stabilization of a discernible symptom), physiologically, (e.g., through stabilization of a physical parameter), or both. In yet another embodiment, “treat,” “treating,” or “treatment” refers to preventing or delaying the onset or development or progression of the disease or disorder. [054] As used herein, a subject is “in need of” a treatment if such subject would benefit biologically, medically or in quality of life from such treatment. [055] Additionally, unless otherwise stated, structures described herein are also meant to include compounds that differ only in the presence of one or more isotopically enriched atoms.
  • compounds having the present structures except for the replacement of hydrogen by deuterium ( 2 H) or tritium ( 3 H), or the replacement of a carbon by a 13 C- or 14 C-carbon atom are within the scope of this disclosure.
  • Such compounds may be useful as, for example, analytical tools, probes in biological assays, or therapeutic agents.
  • R 3 wherein: X is CH or N; Y is CH or N; A is chosen from -C(O)-, -SO 2 -, -S(O)-, -O-, -S-, -NH-, -N(C 1 -C 5 alkyl)-, and -C(O)NH(C 1 - C 5 alkyl)-; R 1 is chosen from H, C 1 -C 3 alkyl, C 1 -C 3 haloalkyl, dialkylamino group, amino group, -CN, hydroxyl, C 1 -C 4 alkoxy, and halogen; each R 2 and R 3 is independently chosen from H, halogen, -CN, hydroxyl, dialkylamino group,
  • the compound of Formula (I) may be a compound of Formula (IA): .
  • the compound of Formula (I) may be a compound of Formula [058]
  • A is -O- or -C(O)-NH-CH 2 .
  • A is -O-.
  • A is -C(O)-NH-CH 2 .
  • R 1 is chosen from H, C 1 -C 3 alkyl, C 1 -C 3 haloalkyl, and halogen.
  • R 1 is chosen from H, F, Cl, Br, I, -CF 3 , -CH 3 , and .
  • R 1 is H. In some embodiments, R 1 is Br. In some embodiments, R 1 is Cl. In some embodiments, R 1 is F. In some embodiments, R 1 is I. [060] In some embodiments, R 2 and R 3 are each independently chosen from H, -OCD 3 , -CD 3 , halogen, C 1 -C 4 alkyl, and C 1 -C 4 alkoxy. In some embodiments, R 2 and R 3 are each H. In some embodiments, R 2 is H and R 3 is F. In some embodiments, R 2 is F and R 3 is H. In some embodiments, R 2 is -OCH 3 and R 3 is F.
  • R 2 is F and R 3 is -OCH 3 . In some embodiments, R 2 is -OCD 3 and R 3 is F. In some embodiments, R 2 is - F and R 3 is or -OCD 3 . In some embodiments, R 2 is -CD 3 and R 3 is F. In some embodiments, R 2 is - F and R 3 is -CD 3 . [061] In some embodiments, R 4 is chosen from H, halogen, -CN, and C 1 -C 4 haloalkyl. In some embodiments, R 4 is H. In some embodiments, R 4 is halogen. In some embodiments, R 4 is F. In some embodiments, R 4 is Cl. In some embodiments, R 4 is Br.
  • compositions of the present disclosure comprise at least one compound of Formula (I) (e.g. Formula (IA), Formula (IB)), or tautomer, stereoisomer or a mixture of stereoisomers, or a pharmaceutically acceptable salt, or hydrate, or deuterated derivative thereof formulated together with one or more pharmaceutically acceptable carriers.
  • These formulations include those suitable for oral, rectal, topical, buccal and parenteral (e.g., subcutaneous, intramuscular, intradermal, or intravenous) administration.
  • Formulations suitable for oral administration may be presented in discrete units, such as capsules, cachets, lozenges, or tablets, each containing a predetermined amount of a compound of the present disclosure as powder or granules; as a solution or a suspension in an aqueous or non-aqueous liquid; or as an oil-in-water or water-in-oil emulsion.
  • such formulations may be prepared by any suitable method of pharmacy which includes the step of bringing into association at least one compound of the present disclosure as the active compound and a carrier or excipient (which may constitute one or more accessory ingredients).
  • the carrier must be acceptable in the sense of being compatible with the other ingredients of the formulation and must not be deleterious to the recipient.
  • the carrier may be a solid or a liquid, or both, and may be formulated with at least one compound described herein as the active compound in a unit-dose formulation, for example, a tablet, which may contain from about 0.05% to about 95% by weight of the at least one active compound.
  • Other pharmacologically active substances may also be present including other compounds.
  • the formulations of the present disclosure may be prepared by any of the well-known techniques of pharmacy consisting essentially of admixing the components.
  • conventional nontoxic solid carriers include, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharin, talc, cellulose, glucose, sucrose, magnesium carbonate, and the like.
  • Liquid pharmacologically administrable compositions can, for example, be prepared by, for example, dissolving or dispersing, at least one active compound of the present disclosure as described herein and optional pharmaceutical adjuvants in an excipient, such as, for example, water, saline, aqueous dextrose, glycerol, ethanol, and the like, to thereby form a solution or suspension.
  • suitable formulations may be prepared by uniformly and intimately admixing the at least one active compound of the present disclosure with a liquid or finely divided solid carrier, or both, and then, if necessary, shaping the product.
  • a tablet may be prepared by compressing or molding a powder or granules of at least one compound of the present disclosure, which may be optionally combined with one or more accessory ingredients.
  • Compressed tablets may be prepared by compressing, in a suitable machine, at least one compound of the present disclosure in a free-flowing form, such as a powder or granules, which may be optionally mixed with a binder, lubricant, inert diluent and/or surface active/dispersing agent(s).
  • Molded tablets may be made by molding, in a suitable machine, where the powdered form of at least one compound of the present disclosure is moistened with an inert liquid diluent.
  • Formulations suitable for buccal (sub-lingual) administration include lozenges comprising at least one compound of the present disclosure in a flavored base, usually sucrose and acacia or tragacanth, and pastilles comprising the at least one compound in an inert base such as gelatin and glycerin or sucrose and acacia.
  • Formulations of the present disclosure suitable for parenteral administration comprise sterile aqueous preparations of at least one compound of Formula (I) (e.g.
  • These preparations are administered intravenously, although administration may also be effected by means of subcutaneous, intramuscular, or intradermal injection.
  • Such preparations may conveniently be prepared by admixing at least one compound described herein with water and rendering the resulting solution sterile and isotonic with the blood.
  • Injectable compositions according to the present disclosure may contain from about 0.1 to about 5% w/w of the active compound.
  • Formulations suitable for rectal administration are presented as unit-dose suppositories.
  • Formulations suitable for topical application to the skin may take the form of an ointment, cream, lotion, paste, gel, spray, aerosol, or oil. Carriers and excipients which may be used include Vaseline, lanoline, polyethylene glycols, alcohols, and combinations of two or more thereof.
  • the active compound i.e., at least one compound of Formula (I) (e.g.
  • Formula (IA), Formula (IB)), or a tautomer, stereoisomer or a mixture of stereoisomers, or a pharmaceutically acceptable salt, or hydrate, or deuterated derivative thereof) is generally present at a concentration of from about 0.1% to about 15% w/w of the composition, for example, from about 0.5 to about 2%.
  • the amount of active compound administered may be dependent on the subject being treated, the subject's weight, the manner of administration and the judgment of the prescribing physician. For example, a dosing schedule may involve the daily or semi-daily administration of the encapsulated compound at a perceived dosage of about 1 ⁇ g to about 1000 mg.
  • intermittent administration such as on a monthly or yearly basis, of a dose of the encapsulated compound may be employed.
  • Encapsulation facilitates access to the site of action and allows the administration of the active ingredients simultaneously, in theory producing a synergistic effect.
  • physicians will readily determine optimum dosages and will be able to readily modify administration to achieve such dosages.
  • a therapeutically effective amount of a compound or composition disclosed herein can be measured by the therapeutic effectiveness of the compound. The dosages, however, may be varied depending upon the requirements of the patient, the severity of the condition being treated, and the compound being used. In one embodiment, the therapeutically effective amount of a disclosed compound is sufficient to establish a maximal plasma concentration.
  • Toxicity and therapeutic efficacy can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., for determining the LD 50 (the dose lethal to 50% of the population) and the ED50 (the dose therapeutically effective in 50% of the population).
  • the dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio LD50/ED50.
  • Compositions that exhibit large therapeutic indices are preferable.
  • Data obtained from the cell culture assays or animal studies can be used in formulating a range of dosage for use in humans.
  • Therapeutically effective dosages achieved in one animal model may be converted for use in another animal, including humans, using conversion factors known in the art (see, e.g., Freireich et al., Cancer Chemother. Reports 50(4):219-244 (1966) and the following Table for Equivalent Surface Area Dosage Factors). Table 2. Equivalent Surface Area Dosage Factors. [077]
  • the dosage of such compounds lies preferably within a range of circulating concentrations that include the ED 50 with little or no toxicity. The dosage may vary within this range depending upon the dosage form employed and the route of administration utilized. Generally, a therapeutically effective amount may vary with the subject's age, condition, and gender, as well as the severity of the medical condition in the subject.
  • a compound of Formula (I) e.g. Formula (IA), Formula (IB)
  • a tautomer, stereoisomer or a mixture of stereoisomers, or a pharmaceutically acceptable salt, or hydrate, or deuterated derivative thereof is administered to treat a condition which is modulated by BTK in a subject in need thereof.
  • the condition modulated by BTK is chosen from cancer, immunological disease, autoimmune diseases, and inflammatory diseases.
  • the disease is inflammatory disease such as arthritis, kidney disease, or cancer, such as leukemia and lymphoma, for example chronic lymphocytic leukemia (CLL), multiple myeloma, and small lymphocytic lymphoma (SLL), and B-cell non-Hodgkin lymphoma.
  • CLL chronic lymphocytic leukemia
  • SLL small lymphocytic lymphoma
  • B-cell non-Hodgkin lymphoma B-cell non-Hodgkin lymphoma.
  • the disease is an autoimmune disease.
  • the disease is rheumatoid arthritis.
  • the autoimmune disease is lupus.
  • the subject in need is suffering from a heteroimmune condition or disease, e.g., graft versus host disease, transplantation, transfusion, anaphylaxis, allergy, type I hypersensitivity, allergic conjunctivitis, allergic rhinitis, or atopic dermatitis.
  • a heteroimmune condition or disease e.g., graft versus host disease, transplantation, transfusion, anaphylaxis, allergy, type I hypersensitivity, allergic conjunctivitis, allergic rhinitis, or atopic dermatitis.
  • the subject in need is suffering from an inflammatory disease, e.g., asthma, appendicitis, blepharitis, bronchiolitis, bronchitis, bursitis, cervicitis, cholangitis, cholecystitis, colitis, conjunctivitis.
  • the subject in need is suffering from a cancer.
  • the cancer is a B-cell proliferative disorder, e.g., diffuse large B cell lymphoma, follicular lymphoma, lymphoma, chronic lymphocytic leukemia, B-cell prolymphocytic leukemia, lymphoplamascytic lymphoma, Waldenström macroglobulinemia, splenic marginal zone lymphoma, plasma cell myeloma, plasmacytoma, extranodal marginal zone B cell lymphoma, nodal marginal zone B cell lymphoma, mantle cell lymphoma, mediastinal (thymic) large B cell lymphoma, intravascular large B cell lymphoma, primary effusion lymphoma, burkitt lymphoma/leukemia, or lymphomatoid granulomatosis.
  • B-cell proliferative disorder e.g., diffuse large B cell lymphoma, follicular lymphoma, lymphoma, chronic lymphocytic leukemia
  • the condition is chosen from B-cell malignancy, B-cell lymphoma, diffuse large B cell lymphoma, chronic lymphocyte leukemia, non-Hodgkin lymphoma, mantle cell lymphoma, follicular lymphoma, hairy cell leukemia B-cell non-Hodgkin lymphoma, marginal zone lymphoma, Waldenström’s macroglobulinemia, multiple myeloma, bone cancer, bone metastasis, arthritis, multiple sclerosis, osteoporosis, irritable bowel syndrome, inflammatory bowel disease, Crohn's disease, lupus, Sjogren’s syndrome, and disorders associated with renal transplant.
  • the condition is mantle cell lymphoma. In some embodiments, the condition is chronic lymphocytic leukemia and small lymphocytic lymphoma. In some embodiments, the condition is Waldenström’s macroglobulinemia. In some embodiments, the condition is marginal zone lymphoma.
  • the subject in need is suffering from a heteroimmune condition or disease, e.g., graft versus host disease (GVHD). In some embodiments, the GVHD is acute GVHD. In some embodiments, the GVHD is chronic GVHD.
  • a compound of Formula (I) e.g.
  • the invention provides for methods for degrading BTK in a cell, comprising contacting the cell with an effective amount of a compound of Formula (I) (e.g. Formula (IA), Formula (IB)), pharmaceutically acceptable salts thereof or pharmaceutical compositions containing the compound or pharmaceutically acceptable salt thereof.
  • a compound of Formula (I) e.g. Formula (IA), Formula (IB)
  • pharmaceutically acceptable salts thereof or pharmaceutical compositions containing the compound or pharmaceutically acceptable salt thereof e.g. Formula (IA), Formula (IB)
  • the contacting is in vitro.
  • the contacting is in vivo.
  • contacting refers to the bringing together of indicated moieties in an in vitro system or an in vivo system.
  • “contacting” a BTK with a compound provided herein includes the administration of a compound provided herein to an individual or patient, such as a human, having a condition which is modulated by BTK, as well as, for example, introducing a compound provided herein into a sample containing a cellular or purified preparation containing the BTK.
  • concentration and route of administration to the patient will vary depending on the condition to be treated.
  • a compound of Formula (I) e.g.
  • Formula (IA), Formula (IB)), or a tautomer, stereoisomer, pharmaceutically acceptable salt, or hydrate thereof, or deuterated derivatives thereof, is administered in combination with other therapeutic agent.
  • these therapeutic agents comprise chemotherapeutic agents, steroids, immunotherapeutic agents, targeted therapies, antibody drug conjugates, B cell receptor pathway inhibitors, antibodies, B cell receptor signaling inhibitors, PI3K inhibitors, IAP inhibitors, mTOR inhibitors, radio immunotherapeutics, DNA damaging agents, proteosome inhibitors, histone deacetylase inhibitors, protein kinase inhibitors, hedgehog inhibitors, Hsp90 inhibitors, telomerase inhibitors, Jak1/2 inhibitors, protease inhibitors, BCL2 inhibitors, PKC inhibitors and PARP inhibitors.
  • these therapeutic agents are chlorambucil, ifosphamide, doxorubicin, mesalazine, thalidomide, lenalidomide, temsirolimus, everolimus, fludarabine, fostamatinib, paclitaxel, docetaxel, ofatumumab, rituximab, dexamethasone, prednisone, CAL-101, ibritumomab, tositumomab, bortezomib, pentostatin, endostatin, bendamustine, cyclophosphamide, vincristine, Venetoclax and lenalidomide.
  • the chemical entities described herein can be synthesized according to one or more illustrative schemes herein and/or techniques well known in the art. Unless specified to the contrary, the reactions described herein take place at atmospheric pressure, generally within a temperature range from about -10° C to about 200° C. Further, except as otherwise specified, reaction times and conditions are intended to be approximate, e.g., taking place at about atmospheric pressure within a temperature range of about -10° C to about 200° C over a period that can be, for example, about 1 to about 24 hours; reactions left to run overnight in some embodiments can average a period of about 16 hours.
  • Isolation and purification of the chemical entities and intermediates described herein can be effected, if desired, by any suitable separation or purification procedure such as, for example, filtration, extraction, crystallization, column chromatography, thin-layer chromatography or thick-layer chromatography, or a combination of these procedures.
  • any suitable separation or purification procedure such as, for example, filtration, extraction, crystallization, column chromatography, thin-layer chromatography or thick-layer chromatography, or a combination of these procedures.
  • suitable separation or purification procedure such as, for example, filtration, extraction, crystallization, column chromatography, thin-layer chromatography or thick-layer chromatography, or a combination of these procedures. See, e.g., Carey et al. Advanced Organic Chemistry, 3 rd Ed., 1990 New York: Plenum Press; Mundy et al., Name Reaction and Reagents in Organic Synthesis, 2 nd Ed., 2005 Hoboken, NJ: J. Wiley & Sons.
  • protecting groups for sensitive or reactive groups may be employed where necessary, in accordance with general principles of chemistry.
  • Protecting groups are manipulated according to standard methods of organic synthesis (T.W. Greene and P.G.M. Wuts (1999) Protective Groups in Organic Synthesis, 3 rd Ed., John Wiley & Sons). These groups may be removed at a convenient stage of the compound synthesis using methods that are readily apparent to those skilled in the art.
  • the (R)- and (S)-isomers of the nonlimiting exemplary compounds can be resolved by methods known to those skilled in the art, for example, by formation of diastereoisomeric salts or complexes which can be separated, e.g., by crystallization; via formation of diastereoisomeric derivatives which can be separated, e.g., by crystallization, gas-liquid or liquid chromatography; selective reaction of one enantiomer with an enantiomer-specific reagent, e.g., enzymatic oxidation or reduction, followed by separation of the modified and unmodified enantiomers; or gas-liquid or liquid chromatography in a chiral environment, e.g., on a chiral support, such as silica with a bound chiral ligand or in the presence of a chiral solvent.
  • a chiral environment e.g., on a chiral support, such as silica with a bound chiral ligand
  • a specific enantiomer can be synthesized by asymmetric synthesis using optically active reagents, substrates, catalysts or solvents, or by converting one enantiomer to the other by asymmetric transformation.
  • the compounds described herein can be optionally contacted with a pharmaceutically acceptable acid to form the corresponding acid addition salts.
  • the compounds described herein can be optionally contacted with a pharmaceutically acceptable base to form the corresponding basic addition salts.
  • disclosed compounds can generally be synthesized by an appropriate combination of generally well-known synthetic methods. Techniques useful in synthesizing these chemical entities are both readily apparent and accessible to those of skill in the relevant art, based on the instant disclosure.
  • EA Ethyl acetate 6.
  • EDCI 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide 7.
  • FA Formic acid 8.
  • HATU 1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5- b]pyridinium 3-oxid hexafluorophosphate 9.
  • HPLC High pressure liquid chromatography 10.
  • LC/MS Liquid chromatography/Mass spectroscopy 11.
  • NMM N-Methylmorpholine 12.
  • NMR Nuclear magnetic resonance 13.
  • PE Petroleum ether 14.
  • TEA Triethylamine 15.
  • TFA Trifluoroacetic acid 16.
  • THF Tetrahydrofuran 17.
  • Scheme 6 Method for the preparation of compounds 12 and 18 [0101] The following compounds were prepared according to Scheme 3: compounds 22, 23, 28 and 31. [0102] The following compounds were prepared according to Scheme 4: compounds 13, 21, 24, and 25. [0103] The following compounds were prepared according to Scheme 6: compounds 15, 26, 27, 29, 30, and 34.
  • Scheme 7 Method for the preparation of compound 32 Compound 33 can be prepared using a similar method as described in the synthesis of compound 32.
  • Scheme 8 Method for the preparation of compounds 35, 36, and 38 Compound 39, 40 and 41 can be prepared using methods as described in Scheme 8.
  • Scheme 9 Method for the preparation of compounds 37 and 48 Compounds 42 and 43 can be synthesized using similar methods as described in Scheme 9.
  • Scheme 10 Method for the preparation of compound 44
  • Compounds 45, 46 and 47 can be synthesized using similar methods as described in the preparation of compound 44.
  • Scheme 11 Method for the preparation of compounds 49, 50, 51, 59, and 70
  • Compounds 65, 66, 67, 68, 69, 81, 82 and 85 can be synthesized using similar methods as described in Scheme 11.
  • Scheme 12 Method for the preparation of compounds 52, 53, 54, 56, 57, 58, 60 and 61
  • Scheme 13 Method for the preparation of compounds 71, 72, 78 and 80
  • Compound 79 can be synthesized with a similar method as described in Scheme 13.
  • Scheme 14 Method for the preparation of compounds 73 and 74
  • Compounds 75, 76 and 77 can be prepared using similar methods as described in Scheme 14.
  • Scheme 15 Method for the preparation of compounds 83 and 84
  • Scheme 16 Method for the preparation of compounds 86 and 87
  • Scheme 17 Method for the preparation of compounds 88-91 and 100-101
  • Compound 93, 94, 95, 96, 97, 98, 99, 102, 103 and 104 can be prepared using similar methods as described in Scheme 11.
  • Scheme 18 Method for the preparation of compounds 105-108 Compound 109 can be synthesized using a similar method as described in Scheme 18.
  • Step 1 Preparation of methyl 2-chloro-4-phenoxybenzoate [0104] The mixture of methyl 2-chloro-4-fluorobenzoate (20 g, 106.1 mmol), phenol (13 g, 137.9mmol) and cesium carbonate (51.83 g, 156.1 mmol) in N,N-dimethylformamide (200 mL) was stirred for 16 h at 90 o C.
  • Step 2 Preparation of (2-chloro-4-phenoxyphenyl)(4-chloro-7H-pyrrolo[2,3-d]pyrimidin-5-yl)methanone
  • 5-Bromo-4-chloro-7h-pyrrole [2,3-d] pyrimidine (1 g, 4.3mmol) was dissolved in tetrahydrofuran (25 mL) and to this was added dropwise slowly n-BuLi (2.5 M in Hexane, 2 eq) at -78 °C under Ar. The mixture was stirred for 1 hour at -78 °C followed by addition of the solution of methyl 2- chloro-4-phenoxybenzoate(1.1 eq) dropwise.
  • Step 3 Preparation of tert-butyl (R)-3-((5-(2-chloro-4-phenoxybenzoyl)-7H-pyrrolo[2,3-d]pyrimidin-4- yl)amino)piperidine-1-carboxylate
  • (2-chloro-4-phenoxyphenyl)(4-chloro- 7H-pyrrolo[2,3-d]pyrimidin-5-yl)methanone (1g, 2.6 mmol)
  • DIEA (3 eq)
  • tert-butyl (R)-3- aminopiperidine-1-carboxylate 1.2 eq
  • isopropanol (12 mL).
  • Step 4 Preparation of (R)-(2-chloro-4-phenoxyphenyl)(4-(piperidin-3-ylamino)-7H-pyrrolo[2,3- d]pyrimidin-5-yl)methanone [0107] To a solution of tert-butyl (R)-3-((5-(2-chloro-4-phenoxybenzoyl)-7H-pyrrolo[2,3- d]pyrimidin-4-yl)amino)piperidine-1-carboxylate (11 g, 20.07 mmol) in 250 mL dioxane was added 4N HCl in dioxane (50 mL). The mixture reaction was stirred for 2.0 hr at room temperature.
  • Step 2 Preparation of (2-chloro-4-phenoxyphenyl)(4-(piperidin-4-ylamino)-7H-pyrrolo[2,3-d]pyrimidin- 5-yl)methanone hydrochloride
  • tert-butyl-4-((5-(2-chloro-4-phenoxybenzoyl)-7H-pyrrolo[2,3- d]pyrimidin-4-yl)amino)piperidine-1-carboxylate 10 g, 18.3 mmol
  • 4N HCl in dioxane 50 mL
  • Step 2 Preparation of 5-fluoro-2-methoxy-N-[[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2- yl)phenyl]methyl]benzamide
  • N-[(4-bromophenyl)methyl]-5-fluoro-2-methoxy-benzamide (46 g, 136 mmol, 1.0 eq) and 4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3,2- dioxaborolane (51.8 g, 204 mmol, 1.5 eq) in dioxane (500 mL) was added potassium acetate (26.7 g, 272 mmol, 2.0 eq) and 1,1-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (9.95 g, 13.6 mmol, 0.1
  • Step 3 Preparation of N-(4-(4-amino-1H-pyrazolo[3,4-d]pyrimidin-3-yl)benzyl)-5-fluoro-2- methoxybenzamideA mixture of 5-fluoro-2-methoxy-N-[[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2- yl)phenyl]methyl]benzamide (10.0 g, 26.0 mmol, 1.0 eq), 3-iodo-1H-pyrazolo[3,4-d]pyrimidin-4-amine (6.78 g, 26.0 mmol, 1.0 eq), 1,1-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (3.80 g, 5.19 mmol, 0.2 eq), potassium phosphate (16.5 g, 77.9 mmol, 3.0 eq) in dioxane (200 mL) and water (40
  • Step 4 Preparation of N-[[4-[4-amino-1-[4-[4-(dimethoxymethyl)-1-piperidyl]-3-fluoro- phenyl]pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]methyl]-5-fluoro-2-methoxy-benzamide [0114] To a solution of N-[[4-(4-amino-1H-pyrazolo[3,4-d]pyrimidin-3-yl)phenyl]methyl]-5- fluoro-2-methoxy-benzamide (12.0 g, 30.6 mmol, 1.0 eq) and 4-(dimethoxymethyl)-1-(2-fluoro-4-iodo- phenyl)piperidine (11.6 g, 30.6 mmol, 1.0 eq) in dimethyl sulfoxide (150 mL) were added copper iodide (3.24 g, 17.0 mmol, 0.55 eq),
  • the suspension was degassed under vacuum and purged with nitrogen for three times. The mixture was stirred under nitrogen at 110 °C for 12 h.
  • the solution was partitioned between ethyl acetate (800 mL) and water (2.0 L). The separated aqueous layer was extracted with ethyl acetate (700 mL x 3). The combined organic layers were washed with brine (500 mL), dried over anhydrous sodium sulfate, filtered and concentrated to give crude product (15 g). The crude product was dissolved in ethyl acetate (420 mL) with refluxing. Then the solution was cooled to ambient temperature along with little precipitate formed and the mixture was kept in refrigerator ( ⁇ 5 °C) for 48 h.
  • Step 1 Preparation of methyl 2-bromo-4,5-difluorobenzoate [0115] Thionyl chloride(13 g, 0.11 mol) was added slowly to a mixture of 2-bromo-4,5- difluorobenzoic acid (20 g, 0.084 mol) in MeOH (60 mL) at 10°C, then stirred at 80°C for 3 h. TLC showed the reaction was completed. The mixture was cooled to room temperature, concentrated then partitioned between ethyl acetate and water. The organic layer was washed with saturated Na2CO3 and brine twice, dried over Na 2 SO 4 and concentrated to afford a crude desired product (21 g, yield: 100%) which was used for the next step without further purification.
  • Step 2 Preparation of tert-butyl 4-(5-bromo-2-fluoro-4-(methoxycarbonyl)phenyl) piperazine-1- carboxylate
  • a mixture of methyl 2-bromo-4,5-difluorobenzoate (21 g, 0.084 mol), tert-butyl piperazine-1-carboxylate (23.4 g, 0.125 mol) and K 2 CO 3 (17.3 g, 0.125 mol) in N,N-dimethylacetamide (60 mL) was stirred at 80 °C for 16 h. TLC showed the reaction was completed. The mixture was added to water (200 mL) and stirred for 10 min. EtOAc (200 mL) was added.
  • Step 3 Preparation of tert-butyl 4-(5-cyano-2-fluoro-4-(methoxycarbonyl)phenyl) piperazine-1- carboxylate [0117] A mixture of tert-butyl 4-(5-bromo-2-fluoro-4-(methoxycarbonyl)phenyl)piperazine-1- carboxylate (30.6 g, 0.073 mol) and CuCN (9.8 g, 0.11 mol) in DMF (120 mL) was stirred at 100°C for 16 h.
  • Step 4 Preparation of tert-butyl 4-(2-fluoro-5-formyl-4-(methoxycarbonyl)phenyl) piperazine-1- carboxylate [0118] To a solution of pyridine (39.1 g, 495 mmol), water (20 mL), acetic acid (26.4 g, 440 mmol) was added tert-butyl 4-(5-cyano-2-fluoro-4-(methoxycarbonyl)phenyl)piperazine-1-carboxylate (20 g, 55 mmol) and Raney-nickel (85% in water, 10 g) at room temperature. The resulting mixture was heated to 60 °C.
  • Step 5 Preparation of tert-butyl (S)-4-(2-(1-amino-5-(tert-butoxy)-1,5-dioxopentan-2-yl)-6-fluoro-1- oxoisoindolin-5-yl)piperazine-1-carboxylate [0119] To a solution of tert-butyl 4-(2-fluoro-5-formyl-4-(methoxycarbonyl)phenyl)piperazine- 1-carboxylate (8.15 g, 22 mmol) in methanol (50 mL) was added tert-butyl (S)-4,5-diamino-5- oxopentanoate (5.4 g, 27 mmol) at room temperature.
  • Step 6 Preparation of (S)-3-(6-fluoro-1-oxo-5-(piperazin-1-yl)isoindolin-2-yl)piperidine-2,6-dione benzenesulfonic acid [0120] To a solution of tert-butyl (S)-4-(2-(1-amino-5-(tert-butoxy)-1,5-dioxopentan-2-yl)-6- fluoro-1-oxoisoindolin-5-yl)piperazine-1-carboxylate (6.7 g, 13 mmol) in acetonitrile (67 mL) was added benzenesulfonic acid (4.3 g, 26 mmol).
  • Step 1 Preparation of 2-(2,6-dioxopiperidin-3-yl)-5-hydroxyisoindoline-1,3-dione [0121] To a solution of 3-aminopiperidine-2,6-dione HCl salt (4.1 g, 24.7 mmol) in acetic acid (45 mL) was added sodium acetate (4.1 g, 49.4 mmol) and the mixture was stirred at 25 o C for 1 hr.4- Hydroxyphthalic acid (3.0g, 16.5 mmol) was added into the mixture and heated to 120 o C for 11 hr. The mixture was concentrated and then poured into water (20 mL). The suspension was filtered.
  • 3-aminopiperidine-2,6-dione HCl salt 4.1 g, 24.7 mmol
  • sodium acetate 4.1 g, 49.4 mmol
  • Step 3 Preparation of tert-butyl 6-(4-(7-hydroxyheptyl)piperazin-1-yl)nicotinate [0123] To a solution of tert-butyl 6-(piperazin-1-yl)nicotinate (526 mg, 2 mmol), 7- bromoheptan-1-ol (468 mg, 2.4 mmol) in CH 3 CN (5 mL) was added K 2 CO 3 at room temperature and the reaction mixture was stirred at 85 o C for 4 hr. The mixture was diluted with EtOAc and filtered through a celite pad.
  • Step 4 Preparation of tert-butyl 6-(4-(7-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5- yl)oxy)heptyl)piperazin-1-yl)nicotinate
  • tert-butyl 6-(4-(7-hydroxyheptyl)piperazin-1-yl)nicotinate 377 mg, 1 mmol
  • 2-(2,6-dioxopiperidin-3-yl)-5- hydroxyisoindoline-1,3-dione 383.6 mg, 1.4 mmol
  • PPh 3 524 mg, 2.0 mmol
  • Step 5 Preparation of 6-(4-(7-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5- yl)oxy)heptyl)piperazin-1-yl)nicotinic acid
  • a solution of tert-butyl 6-(4-(7-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5- yl)oxy)heptyl)piperazin-1-yl)nicotinate 80 mg, 0.13 mmol
  • TFA/DCM 6.0 mL, 1:5
  • Step 2 Preparation of tert-butyl 6-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1- yl)nicotinate
  • 2-(2,6-Dioxopiperidin-3-yl)-5-fluoroisoindoline-1,3-dione 200 mg, 0.724 mmol
  • tert- butyl 6-(piperazin-1-yl)nicotinate 158 mg, 0.603 mmol
  • K 2 CO 3 167 mg, 1.207 mmol
  • Step 4 Preparation of 5-(4-(5-((R)-3-((5-(2-chloro-4-phenoxybenzoyl)-7H-pyrrolo[2,3-d]pyrimidin-4- yl)amino)piperidine-1-carbonyl)pyridin-2-yl)piperazin-1-yl)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3- dione [0130] To a solution of 6-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1- yl)nicotinic acid (130 mg 0.281 mmol) in DMF (5 mL) was added (R)-(2-chloro-4-phenoxyphenyl)(4- (piperidethyl)(4- (piperidethyl)(4- (piperidethyl)(4
  • Example 4 Preparation of 5-(3-(4-(5-((R)-3-((5-(2-chloro-4-phenoxybenzoyl)-7H-pyrrolo [2,3- d]pyrimidin-4-yl)amino)piperidine-1-carbonyl)pyridin-2-yl)piperazin-1-yl)propoxy)-2-(2,6- dioxopiperidin-3-yl)isoindoline-1,3-dione (Compound 4)
  • Compound 4 was prepared by the same procedure as described for Compound 1 by replacing 7- bromoheptan-1-ol with 3-bromopropan-1-ol in step 3.
  • LCMS: m/z 951.3 [M] + .
  • Example 5 Preparation of 5-(2-(4-(5-((R)-3-((5-(2-chloro-4-phenoxybenzoyl)-7H-pyrrolo[2,3- d]pyrimidin-4-yl)amino)piperidine-1-carbonyl)pyridin-2-yl)piperazin-1-yl)ethoxy)-2-(2,6- dioxopiperidin-3-yl)isoindoline-1,3-dione (Compound 5)
  • Step 1 Preparation of tert-butyl 6-(4-(2-hydroxyethyl)piperazin-1-yl)nicotinate [0131] To a solution of tert-butyl 6-(piperazin-1-yl) nicotinate (800 mg, 3.04 mmol) in 20 mL acetonitrile was added 2-bromoethanol (452 mg 3.65 mmol) and K 2 CO 3 (839 mg 6.08 mmol).
  • Step 2 Preparation of tert-butyl 6-(4-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5- yl)oxy)ethyl)piperazin-1-yl)nicotinate
  • 2-(2,6-dioxopiperidin-3-yl)-5-hydroxyisoindoline-1,3-dione 813 mg, 2.97 mmol
  • Step 3 Preparation of 6-(4-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)ethyl)piperazin- 1-yl)nicotinic acid
  • the solution of tert-butyl 6-(4-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5- yl)oxy)ethyl)piperazin-1-yl)nicotinate (130 mg, 0.23 mol) in DCM/TFA(3:1) was stirred at room temperature for 1hr.
  • Step 4 Preparation of 5-(2-(4-(5-((R)-3-((5-(2-chloro-4-phenoxybenzoyl)-7H-pyrrolo[2,3-d]pyrimidin-4- yl)amino)piperidine-1-carbonyl)pyridin-2-yl)piperazin-1-yl)ethoxy)-2-(2,6-dioxopiperidin-3- yl)isoindoline-1,3-dione [0134] To a solution of 6-(4-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5- yl)oxy)ethyl)piperazin-1-yl)nicotinic acid (120 mg 0.236 mmol) in DMF (30 mL) was added (R)-(2- chloro-4-phenoxyphenyl)(4-(piperidin-3-ylamino)-7H
  • Step 1 Preparation of (R)-6-bromo-1-(3-((5-(2-chloro-4-phenoxybenzoyl)-7H-pyrrolo[2,3-d]pyrimidin-4- yl)amino)piperidin-1-yl)hexan-1-one
  • Step 2 Preparation of 5-(4-(6-((R)-3-((5-(2-chloro-4-phenoxybenzoyl)-7H-pyrrolo[2,3-d]pyrimidin-4- yl)amino)piperidin-1-yl)-6-oxohexyl)piperazin-1-yl)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione [0136] The mixture of (R)-6-bromo-1-(3-((5-(2-chloro-4-phenoxybenzoyl)-7H-pyrrolo[2,3- d]pyrimidin-4-yl)amino)piperidin-1-yl)hexan-1-one (150 mg, 0.20 mmol), 2-(2,6-dioxopiperidin-3-yl)-5- (piperazin-1-yl)isoindoline-1,3-dione (90.9 mg, 0.24
  • Example 8 Preparation of 5-(4-(5-((R)-3-((5-(2-chloro-4-phenoxybenzoyl)-7H-pyrrolo[2,3- d]pyrimidin-4-yl)amino)piperidin-1-yl)pentyl)piperazin-1-yl)-2-(2,6-dioxopiperidin-3- yl)isoindoline-1,3-dione (Compound 8)
  • Step 1 Preparation of (R)-7-bromo-1-(3-((5-(2-chloro-4-phenoxybenzoyl)-7H-pyrrolo[2,3-d]pyri midin- 4-yl)amino)piperidin-1-yl)heptan-1-one [0137] To a solution of 7-bromoheptanoyl chloride (60 mg, 0.26 mmol) in DCM (5 mL) was added (R)-(2-chloro-4-phenoxyphenyl)(4-(piperidin-3-ylamino)-7H-pyrrolo[2,3-d]pyrimidin-5- yl)methanone (145.8 mg, 0.26 mmol) and N,N-diisopropylethylamine (335.4 mg, 2.6 mmol).
  • Step 2 Preparation of 5-(4-(5-((R)-3-((5-(2-chloro-4-phenoxybenzoyl)-7H-pyrrolo[2,3-d]pyrimidin-4- yl)amino)piperidin-1-yl)pentyl)piperazin-1-yl)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione [0138] To a solution of (R)-7-bromo-1-(3-((5-(2-chloro-4-phenoxybenzoyl)-7H-pyrrolo[2,3- d]pyrimidin-4-yl)amino)piperidin-1-yl)heptan-1-one (45 mg, 0.07 mmol) and 2-(2,6-dioxopiperidin-3-yl)- 5-(piperazin-1-yl)isoindoline-1,3-dione (23 mg, 0.06 mmol
  • Example 9 5-(4-((5-((R)-3-((5-(2-chloro-4-phenoxybenzoyl)-7H-pyrrolo[2,3-d]pyrimidin-4- yl)amino)piperidine-1-carbonyl)pyridin-2-yl)methyl)piperazin-1-yl)-2-(2,6-dioxopiperidin-3- yl)isoindoline-1,3-dione (Compound 9)
  • Step 1 Preparation of tert-butyl 6-methylnicotinate [0139] To a solution of 6-methylnicotinic acid (5.2 g, 37.9 mmol) in toluene (150 mL) was added DMAP (520 mg, 3.79 mmol) and Boc2O (12.37g, 56.9 mmol).
  • Step 2 Preparation of tert-butyl 6-(bromomethyl)nicotinate [0140] To a solution of tert-butyl 6-methylnicotinate (590 mg, 3.05 mmol) in carbon tetrachloride (10 mL) was added NBS (440 mg, 2.48 mmol) and AIBN (59 mg 0.3 mmol). The mixture was stirred at 70 °C for 12hr and then diluted with ethyl acetate. After extraction with aqueous sodium chloride solution, the combined organic phase was concentrated under vacuum.
  • NBS 440 mg, 2.48 mmol
  • AIBN 59 mg 0.3 mmol
  • Step 3 Preparation of tert-butyl 6-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1- yl)methyl)nicotinate [0141] To a solution of 2-(2,6-dioxopiperidin-3-yl)-5-(piperazin-1-yl)isoindoline-1,3-dione (520 mg, 1.52 mmol) in CH 3 CN (10 mL) was added DIEA (770mg 5.96 mmol) and the mixture was stirred at room temperature for 20 min.
  • DIEA 770mg 5.96 mmol
  • Step 4 Preparation of 6-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1- yl)methyl)nicotinic acid
  • Step 5 Preparation of 5-(4-((5-((R)-3-((5-(2-chloro-4-phenoxybenzoyl)-7H-pyrrolo[2,3-d]pyrimidin-4- yl)amino)piperidine-1-carbonyl)pyridin-2-yl)methyl)piperazin-1-yl)-2-(2,6-dioxopiperidin-3- yl)isoindoline-1,3-dione [0143] To a solution of 6-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin- 1-yl)methyl)nicotinic acid (220 mg, 0.46 mmol) in
  • Step 2 Preparation of 2-(2,6-dioxopiperidin-3-yl)-5-(4-(piperidin-4-ylmethyl)piperazin-1-yl)isoindoline- 1,3-dione
  • Step 3 Preparation of tert-butyl 6-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl) piperazin- 1-yl)methyl)piperidin-1-yl)nicotinate [0146] To a solution of 2-(2,6-dioxopiperidin-3-yl)-5-(4-(piperidin-4-ylmethyl) piperazin-1- yl)isoindoline-1,3-dione(350 mg, 0.797mmol) in DMSO (20mL) was added tert-butyl 6-chloronicotinate (169 mg, 0.793mmol), L-Proline(70 mg, 10%, K 2 CO 3 (220mg, 1.59mmol) and CuI (
  • Step 4 Preparation of 6-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1- yl)methyl)piperidin-1-yl)nicotinic acid
  • tert-Butyl 6-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1- yl) methyl)piperidin-1-yl)nicotinate (280 mg, 0.133 mmol) was dissolved in DCM (6 mL) and TFA (2 mL).
  • Step 5 Preparation of 5-(4-((1-(5-((R)-3-((5-(2-chloro-4-phenoxybenzoyl)-7H-pyrrolo[2,3-d]pyrimidin-4- yl)amino)piperidine-1-carbonyl)pyridin-2-yl)piperidin-4-yl)methyl)piperazin-1-yl)-2-(2,6-dioxopiperidin- 3-yl)isoindoline-1,3-dione [0148] To a solution of 6-(4-((4-(2-(2,6-dioxopiperidin-3-yl) -1,3-dioxoisoindolin-5-yl) piperazin-1-yl)methyl)piperidin-1-yl)nicotinic acid (110 mg, 0.196 mmol) in DMF (20 mL) was added (R)-(2-chloro-4-phenoxyphenyl)(4-(piperid
  • Step 2 Preparation of 5-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1- yl)pentanoic acid
  • Step 3 Preparation of 5-(4-(5-((R)-3-((5-(2-chloro-4-phenoxybenzoyl)-7H-pyrrolo[2,3-d]pyrimidin-4- yl)amino)piperidin-1-yl)-5-oxopentyl)piperazin-1-yl)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione [0151] To a solution of 5-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1- yl)pentanoic acid (35 mg, 0.08 mmol) and (R)-(2-chloro-4-phenoxyphenyl)(4
  • Example 12 Preparation of 5-(4-(7-(4-((5-(2-chloro-4-phenoxybenzoyl)-7H-pyrrolo[2,3-d] pyrimidin-4-yl)amino)piperidin-1-yl)heptyl)piperazin-1-yl)-2-(2,6-dioxopiperidin-3-yl)isoindoline- 1,3-dione (Compound 12) H Step 1: Preparation of 7-bromoheptanal [0152] To a solution of 7-bromoheptan-1-ol (1 g, 5.52 mmol) in DMSO (30 mL) was added IBX (1.8 g, 6.62 mmol) and the mixture was stirred at room temperature for 12 hrs.
  • IBX 1.8 g, 6.62 mmol
  • Step 2 Preparation of 5-(4-(7-bromoheptyl)piperazin-1-yl)-2-(2,6-dioxopiperidin-3-yl) isoindoline-1,3- dione [0153] To a solution of 2-(2,6-dioxopiperidin-3-yl)-5-(piperazin-1-yl)isoindoline-1,3-dione (260 mg, 0.76 mmol) in DCM (20 mL) was added 7-bromoheptanal (161 mg, 0.83 mmol) at 0 °C and the mixture was stirred for 30 min followed
  • Step 3 Preparation of 5-(4-(7-(4-((5-(2-chloro-4-phenoxybenzoyl)-7H-pyrrolo[2,3-d] pyrimidin-4- yl)amino)piperidin-1-yl)heptyl)piperazin-1-yl)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione [0154] To a solution of 5- (4- (7-bromoheptyl) piperazin-1-yl) -2- (2,6-dioxopiperidin-3-yl) isoindoline-1,3-dione (410 mg, 0.75 mmol) in DMSO (10mL) was added (2-chloro-4-phenoxyphenyl)(4- (piperidin-4-ylamino)-7H-pyrrolo[2,3-d]pyrimidin-5-yl)methanone (472 mg 0.97 mmol) and
  • Step 2 Preparation of (S)-3-(5-(4-(6-(4-((5-(2-chloro-4-phenoxybenzoyl)-7H-pyrrolo[2,3-d]pyrimidin-4- yl)amino)piperidin-1-yl)-6-oxohexyl)piperazin-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione [0156] To a solution of 6-bromo-1-(4-((5-(2-chloro-4-phenoxybenzoyl)-7H-pyrrolo[2,3-d]pyri midin-4-yl)amino)piperidin-1-yl)hexan-1-one (110 mg, 0.18 mmol) in ACN (2 mL) stirred under argon at room temperature was added (S)-3-(1-oxo-5-(piperazin-1-yl)isoindolin-2-yl)pipe
  • Step 2 Preparation of (S)-5-(4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)piperazin-1- yl)pentanoic acid
  • Example 15 5-(4-(6-((R)-3-((5-(2-chloro-4-phenoxybenzoyl)-7H-pyrrolo[2,3-d]pyrimidin-4- yl)amino)piperidin-1-yl)hexyl)piperazin-1-yl)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (Compound 15) Step 1: Preparation of (R)-(2-chloro-4-phenoxyphenyl)(4-((1-(6,6-dimethoxyhexyl)piperidin-3-yl)amino)- 7H-pyrrolo[2,3-d]pyrimidin-5-yl)methanone [0160] A suspension of 6-bromo-1,1-dimethoxyhexane (21 mg, 0.09 mmol), (R)-(2-chloro-4- phenoxyphenyl)(4-(piperidin-3
  • Step 2 Preparation of (R)-6-(3-((5-(2-chloro-4-phenoxybenzoyl)-7H-pyrrolo[2,3-d]pyrimidin-4- yl)amino)piperidin-1-yl)hexanal
  • a solution of (R)-(2-chloro-4-phenoxyphenyl)(4-((1-(6,6-dimethoxypentyl)piperidin-3- yl)amino) -7H-pyrrolo[2,3-d]pyrimidin-5-yl)methanone 50 mg, 0.08 mmol
  • ACN 2 mL
  • TsOH 14 mg, 0.08 mmol
  • HOAc 14 mg, 0.08 mmol
  • Step 3 Preparation of 5-(4-(6-((R)-3-((5-(2-chloro-4-phenoxybenzoyl)-7H-pyrrolo[2,3-d]pyrimidin-4- yl)amino)piperidin-1-yl)hexyl)piperazin-1-yl)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione [0162] A solution of (R)-6-(3-((5-(2-chloro-4-phenoxybenzoyl)-7H-pyrrolo[2,3-d]pyrimidin-4- yl)amino) piperidin-1-yl)hexanal (35 mg, 0.07 mmol), Et 3 N (14 mg, 0.14 mmol) and 2-(2,6- dioxopiperidin-3-yl)-5-(piperazin-1-yl)isoindoline-1,3-dione (27 mg, 0.07
  • Step 1 Preparation of (R)-6-bromo-1-(3-((5-(2-chloro-4-phenoxybenzoyl)-7H-pyrrolo[2,3-d]pyri midin- 4-yl)amino)piperidin-1-yl)hexan-1-one [0163] To a mixture of (R)-(2-chloro-4-phenoxyphenyl)(4-(piperidin-3-ylamino)-7H- pyrrolo[2,3-d]pyrimidin-5-yl)methanone (113 mg, 0.20 mmol) and DIEA (77.8 mg, 0.60 mmol) in DCM (10 mL) was added 6-bromohexanoyl chloride (42.8 mg, 0.20 mmol) at 0 °C.
  • Step 2 Preparation of (S)-3-(5-(4-(6-((R)-3-((5-(2-chloro-4-phenoxybenzoyl)-7H-pyrrolo[2,3- d]pyrimidin-4-yl)amino)piperidin-1-yl)-6-oxohexyl)piperazin-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6- dione [0164] A mixture of (R)-6-bromo-1-(3-((5-(2-chloro-4-phenoxybenzoyl)-7H-pyrrolo[2,3- d]pyrimidin-4-yl)amino)piperidin-1-yl)hexan-1-one (50 mg, 0.08 mmol), (S)-3-(1-oxo-5-(piperazin-1- yl)isoindolin-2-yl)piperidine-2,6-dione (38.8 mg
  • Step 1 Preparation of (R)-7-bromo-1-(3-((5-(2-chloro-4-phenoxybenzoyl)-7H-pyrrolo[2,3-d]pyri midin- 4-yl)amino)piperidin-1-yl)heptan-1-one [0165] To a mixture of (R)-(2-chloro-4-phenoxyphenyl)(4-(piperidin-3-ylamino)-7H- pyrrolo[2,3-d]pyrimidin-5-yl)methanone (113 mg, 0.20 mmol) and DIEA (77.8 mg, 0.60 mmol) in DCM (10 mL) was added 7-bromoheptanoyl chloride (45.7 mg, 0.20 mmol) at 0 °C.
  • Step 2 Preparation of 3-(5-(4-(7-((R)-3-((5-(2-chloro-4-phenoxybenzoyl)-7H-pyrrolo[2,3-d]pyrimidin-4- yl)amino)piperidin-1-yl)-7-oxoheptyl)piperazin-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione [0166] A mixture of (R)-7-bromo-1-(3-((5-(2-chloro-4-phenoxybenzoyl)-7H-pyrrolo[2,3- d]pyrimidin-4-yl)amino)piperidin-1-yl)heptan-1-one (50 mg, 0.08 mmol), (S)-3-(1-oxo-5-(piperazin-1- yl)isoindolin-2-yl)piperidine-2,6-dione (38.8mg, 0.
  • Example 18 Preparation of 5-(4-(6-(4-((5-(2-chloro-4-phenoxybenzoyl)-7H-pyrrolo[2,3- d]pyrimidin-4-yl)amino)piperidin-1-yl)hexyl)piperazin-1-yl)-2-(2,6-dioxopiperidin-3-yl)isoindoline- 1,3-dione (Compound 18) Compound 18 was prepared analogously with the procedure described for Compound 12. LCMS: m/z 436.8 [M+1] 2+ .
  • Example 20 (S)-3-(5-(4-(4-((R)-3-((5-(2-chloro-4-phenoxybenzoyl)-7H-pyrrolo[2,3-d]pyrimidin-4- yl)amino)piperidin-1-yl)-4-oxobutyl)piperazin-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione ( Compound 20 was prepared analogously with the procedure described for Compound 14. LC/MS: 843.6 [M+H] + .
  • Example 22 Preparation of 5-(4-(7-(4-((5-(2-chloro-4-phenoxybenzoyl)-7H-pyrrolo[2,3- d]pyrimidin-4-yl)amino)piperidin-1-yl)-7-oxoheptyl)piperazin-1-yl)-2-(2,6-dioxopiperidin-3- yl)isoindoline-1,3-dione (Compound 22) Compound 22 was prepared analogously with the procedure described for Compound 13. LC/MS: 901.2 [M+H] + .
  • Example 23 Preparation of 5-(4-(4-(4-((5-(2-chloro-4-phenoxybenzoyl)-7H-pyrrolo[2,3- d]pyrimidin-4-yl)amino)piperidin-1-yl)-4-oxobutyl)piperazin-1-yl)-2-(2,6-dioxopiperidin-3- yl)isoindoline-1,3-dione (Compound 23) Compound 23 was prepared analogously with the procedure described for Compound 11. LC/MS: 857.3 [M+H] + .
  • Example 24 Preparation of (S)-3-(5-(4-(4-(4-(4-((5-(2-chloro-4-phenoxybenzoyl)-7H-pyrrolo[2,3- d]pyrimidin-4-yl)amino)piperidin-1-yl)-4-oxobutyl)piperazin-1-yl)-1-oxoisoindolin-2-yl)piperidine- 2,6-dione (Compound 24) Compound 24 was prepared analogously with the procedure described for Compound 14. LC/MS: 843.4 [M+H] + .
  • Step 2 Preparation of (S)-5-(4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)piperazin-1- yl)pentanoic acid
  • tert-Butyl (S)-5-(4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)piperazin-1- yl)pentanoate 250 mg, 0.52 mmol
  • DCM 10 mL
  • TFA 2 mL
  • Step 3 Preparation of (S)-3-(5-(4-(5-(4-((5-(2-chloro-4-phenoxybenzoyl)-7H-pyrrolo[2,3-d]pyrimidin-4- yl)amino)piperidin-1-yl)-5-oxopentyl)piperazin-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione [0170] To a solution of (S)-5-(4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)piperazin-1- yl)pentanoic acid (50 mg, 0.10 mmol), HATU (53.24 mg, 0.14 mmol) and DIEA (45.23 mg
  • Example 26 Preparation of 5-(4-(3-(4-((5-(2-chloro-4-phenoxybenzoyl)-7H-pyrrolo[2,3- d]pyrimidin-4-yl)amino)piperidin-1-yl)propyl)piperazin-1-yl)-2-(2,6-dioxopiperidin-3- yl)isoindoline-1,3-dione (Compound 26) Compound 26 was prepared analogously with the procedure described for Compound 15. LC/MS: 830.5 [M+H] + .
  • Example 27 Preparation of 5-(4-(4-(4-((5-(2-chloro-4-phenoxybenzoyl)-7H-pyrrolo[2,3- d]pyrimidin-4-yl)amino)piperidin-1-yl)butyl)piperazin-1-yl)-2-(2,6-dioxopiperidin-3-yl)isoindoline-
  • Compound 27 was prepared analogously with the procedure described for Compound 15.
  • Example 29 5-(4-(7-((R)-3-((5-(2-chloro-4-phenoxybenzoyl)-7H-pyrrolo[2,3-d]pyrimidin-4- yl)amino)piperidin-1-yl)heptyl)piperazin-1-yl)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (Compound 29) Compound 29 was prepared analogously with the procedure described for Compound 15. LC/MS: 886.3 [M+H] + .
  • Example 30 Preparation of 5-(4-(5-((R)-3-((5-(2-chloro-4-phenoxybenzoyl)-7H-pyrrolo[2,3- d]pyrimidin-4-yl)amino)piperidin-1-yl)pentyl)piperazin-1-yl)-2-(2,6-dioxopiperidin-3- yl)isoindoline-1,3-dione (Compound 30) + Compound 30 was prepared analogously with the procedure described for Compound 15. LC/MS: 857.4 [M+H] + .
  • Step 2 Preparation of (S)-3-(1-oxo-5-(4-(piperidin-4-ylmethyl)piperazin-1-yl)isoindolin-2-yl)piperidine- 2,6-dione
  • Step 3 Preparation of (S)-3-(5-(4-((1-((R)-3-((5-(2-chloro-4-phenoxybenzoyl)-7H-pyrrolo[2,3- d]pyrimidin-4-yl)amino)piperidine-1-carbonyl)piperidin-4-yl)methyl)piperazin-1-yl)-1-oxoisoindolin-2- yl)piperidine-2,6-dione [0173] To a solution of (R)-(2-chloro-4-phenoxyphenyl)(4-(piperidin-3-ylamino)-7H- pyrrolo[2,3-d]pyrimidin-5-yl)methanone (90 mg, 0.16 mmol) in DCM (5 mL
  • Example 33 Preparation of 5-(4-((1-((R)-3-((5-(2-chloro-4-phenoxybenzoyl)-7H-pyrrolo[2,3- d]pyrimidin-4-yl)amino)piperidine-1-carbonyl)piperidin-4-yl)methyl)piperazin-1-yl)-2-((S)-2,6- dioxopiperidin-3-yl)isoindoline-1,3-dione (Compound 33) Compound 33 was prepared analogously with the procedure described for Compound 32. LC/MS: 913.2[M+H] + .
  • Example 34 Preparation of 5-(4-(5-(4-((5-(2-chloro-4-phenoxybenzoyl)-7H-pyrrolo[2,3- d]pyrimidin-4-yl)amino)piperidin-1-yl)pentyl)piperazin-1-yl)-2-(2,6-dioxopiperidin-3- yl)isoindoline-1,3-dione (Compound 34) Step 1: Preparation of 5-(4-(5,5-dimethoxypentyl)piperazin-1-yl)-2-(2,6-dioxopiperidin-3-yl)isoindoline- 1,3-dione [0174] To the solution of 5-bromo-1,1-dimethoxypentane (250 mg, 1.19 mmol) in DMSO (10 mL) was added 2-(2,6-dioxopiperidin-3-yl)-5-(piperazin-1-yl)is
  • Step 2 Preparation of 5-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)pentanal
  • 5-(4-(5,5-dimethoxypentyl)piperazin-1-yl)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3- dione 360 mg, 0.762 mmol
  • 2N HCl/dioxane 10 mL
  • Step 3 Preparation of 5-(4-(5-(4-((5-(2-chloro-4-phenoxybenzoyl)-7H-pyrrolo[2,3-d]pyrimidin-4- yl)amino)piperidin-1-yl)pentyl)piperazin-1-yl)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione [0176] To a solution of (2-chloro-4-phenoxyphenyl)(4-(piperidin-4-ylamino)-7H-pyrrolo[2,3- d]pyrimidin-5-yl)methanone (220 mg 0.492 mmol) in DCM (3 mL) was added potassium acetate (72.3 mg 0.738 mmol).
  • Example 35 Preparation of 4-(9-(4-((5-(2-chloro-4-phenoxybenzoyl)-7H-pyrrolo[2,3-d]pyrimidin-4- yl)amino)piperidin-1-yl)-9-oxonon-1-yn-1-yl)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (Compound 35)
  • Step 1 Preparation of non-8-ynoic acid [0177] To a solution of lithium acetylide-ethylenediamine complex (2.20 g, 21.5 mmol, 90%) in DMSO (5 mL) was added 7-bromoheptanoic acid (1.50 g, 7.17 mmol) in DMSO (7 mL) dropwise at 0 °C. The solution was stirred at room temperature for 2 hours. The reaction mixture was poured into ice/water, acidified with 1N HCl and extracted with DCM. The organic layer was dried over Na 2 SO 4 and concentrated in vacuum.
  • Step 2 Preparation of tert-butyl non-8-ynoate [0178] To a solution of non-8-ynoic acid (900 mg, 5.84 mmol), anhydrous N, N- dimethylformamide (85 mg, 1.17 mmol) in anhydrous DCM (20 mL) stirred under Ar at room temperature was added oxalyl chloride (1.5 g, 11.68 mmol) dropwise. The reaction mixture was stirred at room temperature for 1 hour. The mixture was evaporated under vacuum and the residue was dissolved in anhydrous THF (20 mL). The solution was cooled to 0 °C and t-BuOK (1.3 g, 11.68 mmol) was added portion wise. The mixture was stirred at room temperature for 1 hour.
  • Step 3 Preparation of tert-butyl 9-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl) non-8-ynoate
  • Step 4 Preparation of 9-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl) non-8-ynoic acid
  • a solution of tert-butyl 9-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl) non-8- ynoate (30 mg, 0.06 mmol) in TFA (1 mL) and DCM (3 mL) was stirred at room temperature for 2 hours. The mixture was evaporated under vacuum to give crude product (33 mg) which was used in the next step without further purification.
  • Step 5 Preparation of 4-(9-(4-((5-(2-chloro-4-phenoxybenzoyl)-7H-pyrrolo[2,3-d] pyrimidin-4- yl)amino)piperidin-1-yl)-9-oxonon-1-yn-1-yl)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione [0181] A mixture of 9-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl) non-8-ynoic acid (33 mg, 80 % purity, 0.06 mmol), (2-chloro-4-phenoxyphenyl)(4-(piperidin-4-ylamino)-7H-pyrrolo[2,3- d]pyrimidin-5-yl)methanone (31 mg, 0.070 mmol), HATU (40 mg, 0.11 mmol),
  • Example 36 Preparation of 4-(7-(4-((5-(2-chloro-4-phenoxybenzoyl)-7H-pyrrolo[2,3-d]pyrimidin-4- yl)amino)piperidin-1-yl)-7-oxohept-1-yn-1-yl)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (Compound 36) Compound 36 was prepared analogously with the procedure described for compound 35. LC/MS: 811.4 [M+H] + .
  • Example 37 Preparation of 5-(4-(3-(2-(4-((5-(2-chloro-4-phenoxybenzoyl)-7H-pyrrolo[2,3- d]pyrimidin-4-yl)amino)piperidin-1-yl)-2-oxoethyl)cyclobutyl)piperazin-1-yl)-2-(2,6- dioxopiperidin-3-yl)isoindoline-1,3-dione (Compound 37) Step 1: Preparation of 3-(2-(4-((5-(2-chloro-4-phenoxybenzoyl)-7H-pyrrolo[2,3-d]pyrimidin-4- yl)amino)piperidin-1-yl)-2-oxoethyl)cyclobutan-1-one [0182] To a solution of (3-oxocyclobutyl)acetic acid (250 mg, 1.95 mmol) in DMF (10 ml) stirred at room
  • Step 2 Preparation of 5-(4-(3-(2-(4-((5-(2-chloro-4-phenoxybenzoyl)-7H-pyrrolo[2,3-d]pyrimidin-4- yl)amino)piperidin-1-yl)-2-oxoethyl)cyclobutyl)piperazin-1-yl)-2-(2,6-dioxopiperidin-3-yl)isoindoline- 1,3-dione [0183] To a solution of 3- ⁇ 2-[4-( ⁇ 5-[(2-chloro-4-phenoxyphenyl)carbonyl]-7H-pyrrolo[2,3- d]pyrimidin-4-yl ⁇ amino)piperidin-1-yl]-2-oxoethyl ⁇ cyclobutan-1-one (1 g, 1.79 mmol) in MeOH/DMF/AcOH (8 mL, 4 mL, 0.5 mL) stirred at room temperature was added
  • Example 38 Preparation of 4-(8-(4-((5-(2-chloro-4-phenoxybenzoyl)-7H-pyrrolo[2,3-d]pyrimidin-4- yl)amino)piperidin-1-yl)-8-oxooct-1-yn-1-yl)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (Compound 38) Compound 38 was prepared analogously with the procedure described for compound 35. LC/MS: 825.5 [M+H] + .
  • Example 39 Preparation of 3-(4-(9-(4-((5-(2-chloro-4-phenoxybenzoyl)-7H-pyrrolo[2,3- d]pyrimidin-4-yl)amino)piperi-din-1-yl)-9-oxonon-1-yn-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6- dione (Compound 39) Compound 39 was prepared analogously with the procedure described for compound 35. LC/MS: 825.5 [M+H] + .
  • Example 40 Preparation of 3-(4-(8-(4-((5-(2-chloro-4-phenoxybenzoyl)-7H-pyrrolo[2,3- d]pyrimidin-4-yl)amino) piperidin-1-yl)-8-oxooct-1-yn-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6- dione (Compound 40) Compound 40 was prepared analogously with the procedure described for compound 35. LC/MS: 811.5 [M+H] + .
  • Example 42 Preparation of (S)-3-(5-(4-(3-(2-(4-((5-(2-chloro-4-phenoxybenzoyl)-7H-pyrrolo[2,3- d]pyrimidin-4-yl)amino)piperidin-1-yl)-2-oxoethyl)cyclobutyl)piperazin-1-yl)-1-oxoisoindolin-2- yl)piperidine-2,6-dione (Compound 42) Step 1: Preparation of 3-(2-diazoacetyl)cyclobutan-1-one [0184] To a solution of 3-oxocyclobutane-1-carboxylic acid (2 g, 17.54 mmol) in DCM (10 mL) was added SOCl 2 (3.84 mL).
  • Step 2 Preparation of 2-(3-oxocyclobutyl)acetic acid [0185] To a solution of 3-(2-diazoacetyl)cyclobutan-1-one (1.6 g, 9.27 mmol) in THF (30 mL) and water (15 mL) was added AgNO 3 (1.87 g, 11.12 mmol). The reaction mixture was stirred at room temperature for overnight then evaporated in vacuum to remove THF. The aqueous phase was extracted with EA (20 mL ⁇ 3). The combined organic layer was dried over Na 2 SO 4 and evaporated under vacuum to afford the title compound (1.0 g, 76.4 % yield) as a yellow oil. LC/MS: 127.1 [M-H]-.
  • Step 3 Preparation of 3-(2-(4-((5-(2-chloro-4-phenoxybenzoyl)-7H-pyrrolo[2,3-d]pyrimidin-4- yl)amino)piperidin-1-yl)-2-oxoethyl)cyclobutan-1-one
  • 2-(3-oxocyclobutyl)acetic acid 50 mg, 90 % purity, 0.35 mmol
  • (2- chloro-4-phenoxyphenyl)(4-(piperidin-4-ylamino)-7H-pyrrolo[2,3-d]pyrimidin-5-yl)methanone 207.8 mg, 0.43 mmol
  • HATU 177.9 mg, 0.47mmol
  • N,N-diisopropylethylamine (75.6 mg, 0.59mmol) and DMF (10 mL) was stirred at room temperature for 4 hours.
  • Example 43 Preparation of 5-(4-(3-(2-((R)-3-((5-(2-chloro-4-phenoxybenzoyl)-7H-pyrrolo[2,3- d]pyrimidin-4-yl)amino)piperidin-1-yl)-2-oxoethyl)cyclobutyl)piperazin-1-yl)-2-(2,6- dioxopiperidin-3-yl)isoindoline-1,3-dione (Compound 43) [0188] Compound 43 was prepared using the same method as described in the preparation of compound 42.
  • Step 2 Preparation of 5-(4-(2-(1-(4-((5-(2-chloro-4-phenoxybenzoyl)-7H-pyrrolo[2,3-d]pyrimidin-4- yl)amino)-2-fluorophenyl)piperidin-4-yl)ethyl)piperazin-1-yl)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3- dione [0190] A solution of 2-(1-(4-((5-(2-chloro-4-phenoxybenzoyl)-7H-pyrrolo[2,3-d]pyrimidin-4- yl)amino)-2-fluorophenyl)piperidin-4-yl)acetaldehyde (100 mg, 0.17 mmol), 2-(2,6-dioxopiperidin-3-yl)- 5-(piperazin-1-yl)isoindoline-1,3-dione (64
  • Step 1 Preparation of 1-(4-((5-(2-chloro-4-phenoxybenzoyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2- fluorophenyl)piperidine-4-carbaldehyde
  • Step 2 Preparation of (S)-3-(5-(4-((1-(4-((5-(2-chloro-4-phenoxybenzoyl)-7H-pyrrolo[2,3-d]pyrimidin-4- yl)amino)-2-fluorophenyl)piperidin-4-yl)methyl)piperazin-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6- dione [0193] A solution of 1-(4-((5-(2-chloro-4-phenoxybenzoyl)-7H-pyrrolo[2,3-d]pyrimidin-4- yl)amino)-2-fluorophenyl)piperidine-4-carbaldehyde (70 mg, 0.12 mmol), (S)-3-(1-oxo-5-(piperazin-1- yl)isoindolin-2-yl)piperidine-2,6-dione (60 mg, 0.12 mmol
  • Example 47 Preparation of 5-(4-((1-(4-((5-(2-chloro-4-phenoxybenzoyl)-7H-pyrrolo[2,3- d]pyrimidin-4-yl)amino)-2-fluorophenyl)piperidin-4-yl)methyl)piperazin-1-yl)-2-(2,6- dioxopiperidin-3-yl)isoindoline-1,3-dione (Compound 47) [0194] A solution of 1-(4-((5-(2-chloro-4-phenoxybenzoyl)-7H-pyrrolo[2,3-d]pyrimidin-4- yl)amino)-2-fluorophenyl)piperidine-4-carbaldehyde (70 mg, 0.12 mmol) , 2-(2,6-dioxopiperidin-3-yl)-5- (piperazin-1-yl)isoindoline-1,3-dione (45 mg, 0.
  • Example 48 Preparation of 5-(4-(3-(2-(4-((5-(2-chloro-4-phenoxybenzoyl)-7H-pyrrolo[2,3- d]pyrimidin-4-yl)amino)piperidin-1-yl)-2-oxoethyl)azetidin-1-yl)piperidin-1-yl)-2-(2,6- dioxopiperidin-3-yl)isoindoline-1,3-dione (Compound 48) °C Step 1: Preparation of benzyl 4-(3-(2-(tert-butoxy)-2-oxoethyl)azetidin-1-yl)piperidine-1-carboxylate [0195] To a solution of tert-butyl 2-(azetidin-3-yl)acetate (200 mg, 0.96 mmol) in DCM (5 mL) stirred at room temperature was added Et 3 N (194 mg, 1.92 m
  • Step 2 Preparation of tert-butyl 2-(1-(piperidin-4-yl)azetidin-3-yl)acetate
  • tert-butyl 2-[1-(1- ⁇ 3-[(formyloxy)methyl]phenyl ⁇ piperidin-4- yl)azetidin-3-yl] acetate 255 mg, 0.66 mmol
  • Pd/C 70 mg, 0.66 mmol
  • Step 3 Preparation of tert-butyl 2-(1-(1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl) piperidin- 4-yl)azetidin-3-yl)acetate [0197] To a solution of 2-(2,6-dioxopiperidin-3-yl)-5-fluoroisoindole-1,3-dione (140 mg, 0.55 mmol) in NMP (5 mL) stirred at room temperature was added tert-butyl 2-[1-(piperidin-4-yl)azetidin-3- yl]acetate (140 mg, 0.55 mmol) and DIEA (142 mg, 1.1 mmol).
  • Step 4 Preparation of 2-(1-(1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperidin-4- yl)azetidin-3-yl)acetic acid
  • a solution of tert-butyl 2-(1- ⁇ 1-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-5- yl]piperidin-4-yl ⁇ azetidin-3-yl)acetate 70 mg, 0.14 mmol
  • TFA/DCM(1:5, 6 mL) was stirred at room temperature for 2 hour.
  • Example 49 Preparation of (S)-N-(4-(4-amino-1-(4-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-1- oxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)-3-fluorophenyl)-1H-pyrazolo[3,4- d]pyrimidin-3-yl)benzyl)-5-fluoro-2-methoxybenzamide (Compound 49) Step 1: Preparation of N-(4-bromobenzyl)-5-fluoro-2-methoxybenzamide [0200] A solution of 5-fluoro-2-methoxy-benzoic acid (30 g, 176 mmol, 1.0 eq), O-(7- azabenzotriazol-1-yl)-N,N,N’,N’-tetramethyluronium hexafluorophosphate (80.5 g
  • Step 2 Preparation of 5-fluoro-2-methoxy-N-[[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2- yl)phenyl]methyl]benzamide
  • N-[(4-bromophenyl)methyl]-5-fluoro-2-methoxy-benzamide (46 g, 136 mmol, 1.0 eq) and 4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3,2- dioxaborolane (51.8 g, 204 mmol, 1.5 eq) in dioxane (500 mL) was added potassium acetate (26.7 g, 272 mmol, 2.0 eq) and 1,1-bis(diphenylphosphino) ferrocene]dichloropalladium(II) (9.95 g, 13.6 mmol, 0.1
  • the suspension was degassed under vacuum and purged with nitrogen for three times. The mixture was stirred under nitrogen at 90°C for 12 h. The solution was poured into water (2 L), extracted wit ethyl acetate (1 L ⁇ 3). The combined organic phase was washed with brine (2 L), dried with anhydrous sodium sulfate, filtered and concentrated. The combined crude product was purified by silica gel chromatography with 20% - 30% ethyl acetate in petroleum ether as eluent. The crude product was triturated with petroleum ether (200 mL), filtered and the filter cake was dried under vacuum to afford the desired compound (50 g, 79% yield) as a white solid.
  • Step 4 Preparation of N-[[4-[4-amino-1-[4-[4-(dimethoxymethyl)-1-piperidyl]-3-fluoro- phenyl]pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]methyl]-5-fluoro-2-methoxy-benzamide [0203] To a solution of N-[[4-(4-amino-1H-pyrazolo[3,4-d]pyrimidin-3-yl)phenyl]methyl]-5- fluoro-2-methoxy-benzamide (12.0 g, 30.6 mmol, 1.0 eq) and 4-(dimethoxymethyl)-1-(2-fluoro-4-iodo- phenyl)piperidine (11.6 g, 30.6 mmol, 1.0 eq) in dimethyl sulfoxide (150 mL) were added copper iodide (3.24 g, 17.0 mmol, 0.55 eq),
  • the suspension was degassed under vacuum and purged with nitrogen for three times.
  • the mixture was stirred under nitrogen at 110 °C for 12 h.
  • the reaction mixture was partitioned between ethyl acetate (800 mL) and water (2.0 L).
  • the aqueous layer was extracted with ethyl acetate (700 mL ⁇ 3).
  • the combined organic layers were washed with brine (500 mL), dried over anhydrous sodium sulfate, filtered and concentrated to give crude product (15 g).
  • the crude product was dissolved in ethyl acetate (420 mL) with refluxing and the solution was cooled to ambient temperature and then kept in refrigerator ( ⁇ 5 °C) for 48 h.
  • Step 5 Preparation of N-(4-(4-amino-1-(3-fluoro-4-(4-formylpiperidin-1-yl)phenyl)-1H-pyrazolo [3,4- d]pyrimidin-3-yl)benzyl)-5-fluoro-2-methoxybenzamide
  • a solution of N-(4-(4-amino-1-(4-(4-(dimethoxymethyl)piperidin-1-yl)-3- fluorophenyl)-1H-pyra zolo[3,4-d]pyrimidin-3-yl)benzyl)-5-fluoro-2-methoxybenzamide (1.03 g, 1.60 mmol) in THF (20 mL) and H 2 SO 4 (2 M, 20 ml) was stirred at 70 °C for 1 hour.
  • Step 6 Preparation of (S)-N-(4-(4-amino-1-(4-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5- yl)piperazin-1-yl)methyl)piperidin-1-yl)-3-fluorophenyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)benzyl)-5- fluoro-2-methoxybenzamide [0205] A solution of N-(4-(4-amino-1-(3-fluoro-4-(4-formylpiperidin-1-yl)phenyl)-1H- pyrazolo [3,4-d]pyrimidin-3-yl)benzyl)-5-fluoro-2-methoxybenzamide (900 mg 1.51 mmol), (S)-3-(1- oxo-5-(piperazin-1-yl)isoindolin-2-
  • Example 50 Preparation of N-(4-(4-amino-1-(4-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3- dioxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)-3-fluorophenyl)-1H-pyrazolo[3,4- d]pyrimidin-3-yl)benzyl)-5-fluoro-2-methoxybenzamide (Compound 50) [0206] A solution of N-[(4- ⁇ 4-amino-1-[3-fluoro-4-(4-formylpiperidin-1- yl)phenyl]pyrazolo[3,4-d]pyrimidin-3-yl ⁇ phenyl)methyl]-5-fluoro-2-methoxybenzamide (60 mg, 0.1 mmol), 2-(2,6-dioxopiperidin-3-yl)-5-(piperazin-1-
  • Step 2 Preparation of (S)-N-(4-(4-amino-1-(1-(5-((4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindo lin-5- yl)piperazin-1-yl)methyl)pyridin-2-yl)piperidin-4-yl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl) benzyl)-5- fluoro-2-methoxybenzamide [0209] (S)-2-(2,6-dioxopiperidin-3-yl)-5-fluoro-6-(piperazin-1-yl)isoindoline-1,3-dione benzenesulfonic acid (63 mg, 0.13 mmol) and Et3N (13 mg, 0.13 mmol) was added to MeOH (4 mL).
  • Example 53 Preparation of (S)-N-(4-(4-amino-1-(1-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-1- oxoisoindolin-5-yl)piperazin-1-yl)methyl)phenyl)piperidin-4-yl)-1H-pyrazolo[3,4-d]pyrimidin-3- yl)benzyl)-5-fluoro-2-methoxybenzamide (Compound 53) Step 1: Preparation of tert-butyl 4-(tosyloxy)piperidine-1-carboxylate [0210] To a solution of tert-butyl 4-hydroxypiperidine-1-carboxylate (2 g, 9.94 mmol) in pyridine (20 mL) stirred at room temperature was added TsCl (2.27 g, 11.93 mmol).
  • Step 2 Preparation of tert-butyl 4-(4-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1H- pyrazolo[3,4-d]pyrimidin-1-yl)piperidine-1-carboxylate [0211] To a solution of tert-butyl 4-(tosyloxy)piperidine-1-carboxylate (2.2 g, 6.19 mmol) in DMF (2 mL) stirred at room temperature was added Cs 2 CO 3 (4.03 g, 12.38 mmol) and N-(4-(4-amino- 1H-pyrazolo[3,4-d]pyrimidin-3-yl)benzyl)-5-fluoro-2-methoxybenzamide (2.43 g, 6.19 mmol).
  • Step 3 Preparation of N-(4-(4-amino-1-(piperidin-4-yl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)benzyl)-5- fluoro-2-methoxybenzamide
  • a solution of tert-butyl 4-(4-amino-3-(4-((5-fluoro-2- methoxybenzamido)methyl)phenyl)-1H-pyrazolo[3,4-d] pyrimidin-1-yl)piperidine-1-carboxylate (2.5 g, 4.34 mmol) in TFA/DCM (1:5, 30 mL) was stirred at room temperature for 2 hours. The solution was concentrated in vacuum.
  • Step 4 Preparation of N-(4-(4-amino-1-(1-(4-formylphenyl)piperidin-4-yl)-1H-pyrazolo[3,4-d]pyrimidin- 3-yl)benzyl)-5-fluoro-2-methoxybenzamide
  • N-( ⁇ 4-[4-amino-1-(piperidin-4-yl)pyrazolo[3,4-d]pyrimidin-3- yl]phenyl ⁇ methyl) -5-fluoro-2-methoxybenzamide 700 mg, 1.47 mmol
  • DMF 10 mL
  • 4-fluorobenzaldehyde 365 mg, 2.94 mmol
  • K 2 CO 3 406 mg, 2.94 mmol
  • Step 5 Preparation of (S)-N-(4-(4-amino-1-(1-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindo lin-5- yl)piperazin-1-yl)methyl)phenyl)piperidin-4-yl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)benzyl) -5-fluoro-2- methoxybenzamide [0214] (S)-2-(2,6-dioxopiperidin-3-yl)-5-fluoro-6-(piperazin-1-yl)isoindoline-1,3-dione benzenesulfonic acid (71 mg, 0.15 mmol) and Et3N (15 mg, 0.15 mmol) was added into MeOH (4 mL).
  • Example 54 Preparation of (S)-N-(4-(4-amino-1-(1-(5-((4-(2-(2,6-dioxopiperidin-3-yl)-1- oxoisoindolin-5-yl)piperazin-1-yl)methyl)pyridin-2-yl)azetidin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin- 3-yl)benzyl)-5-fluoro-2-methoxybenzamide (Compound 54) Step 1: Preparation of tert-butyl 3-(tosyloxy)azetidine-1-carboxylate [0215] A solution of tert-butyl 3-hydroxyazetidine-1-carboxylate (1270 mg, 7.33 mmol), Et3N (1113 mg, 11.00 mmol) and TsCl (1677 mg, 8.80 mmol) in DCM (20 mL) was stirred at room temperature under N 2 overnight.
  • Step 2 Preparation of tert-butyl 3-(4-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1H- pyrazolo[3,4-d]pyrimidin-1-yl)azetidine-1-carboxylate
  • a suspension of tert-butyl 3-(tosyloxy)azetidine-1-carboxylate (667 mg, 2.04 mmol), N-(4-(4-amino-1H-pyrazolo[3,4-d]pyrimidin-3-yl)benzyl)-5-fluoro-2-methoxybenzamide (800 mg, 2.04 mmol) and Cs 2 CO 3 (1993 mg, 6.12 mmol) in DMF (10 mL) was stirred at 80 °C overnight.
  • Step 3 Preparation of N-(4-(4-amino-1-(azetidin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)benzyl) -5- fluoro-2-methoxybenzamide
  • Step 4 Preparation of N-(4-(4-amino-1-(1-(5-formylpyridin-2-yl)azetidin-3-yl)-1H-pyrazolo[3,4- d]pyrimidin-3-yl)benzyl)-5-fluoro-2-methoxybenzamide [0218] To a solution of N-(4-(4-amino-1-(azetidin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-3- yl)benzyl)-5-fluoro-2-methoxybenzamide (TFA salt, 198 mg, 0.36 mmol) and 6-bromonicotinaldehyde (136 mg, 0.73 mmol) in DMF (4 mL) was added K 2 CO 3 (151 mg, 1.11 m
  • Step 5 Preparation of (S)-N-(4-(4-amino-1-(1-(5-((4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5- yl)piperazin-1-yl)methyl)pyridin-2-yl)azetidin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)benzyl)-5-fluoro- 2-methoxybenzamide [0219] (S)-2-(2,6-dioxopiperidin-3-yl)-5-fluoro-6-(piperazin-1-yl)isoindoline-1,3-dione benzenesulfonic acid (84 mg, 0.17 mmol) and Et3N (17 mg, 0.17 mmol) was added into MeOH (4 mL).
  • Example 55 Preparation of N-(4-(4-amino-1-(1-(5-(4-(2-((S)-2,6-dioxopiperidin-3-yl)-1- oxoisoindolin-5-yl)piperazin-1-yl)pentanoyl)pyrrolidin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-3- yl)benzyl)-5-fluoro-2-methoxybenzamide (Compound 55) Step 1: Preparation of tert-butyl 5-hydroxypentanoate [0220] To a solution of 5-(tert-butoxy)-5-oxopentanoic acid (3.00 g, 6.96 mmol) in dry THF (60 mL) cooled to 0 °C was added NaBH 4 (630 mg, 16.74 mmol).
  • Step 2 Preparation of tert-butyl 5-oxopentanoate [0221] To a solution of tert-butyl 5-hydroxypentanoate (500 mg, 2.87 mmol) in DCM (20 mL) stirred under argon at room temperature was added PDC (1.62 g, 4.30 mmol). The mixture was stirred at room temperature for 4 hours. The mixture was filtered and the filtration was collected. The filtrate cake was was washed with DCM (20 mL). The combined solution was concentrated in vacuum. The residue was purified by flash chromatography (0 ⁇ 65 % EA in PE) to give the desired product (200 mg, 40.5 %) as a colorless oil.
  • Step 3 Preparation of tert-butyl (S)-5-(4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)pipe razin-1- yl)pentanoate [0222] To a solution of tert-butyl 5-oxopentanoate (90 mg, 0.52 mmol), (S)-3-(1-oxo-5- (piperazin-1-yl)isoindolin-2-yl)piperidine-2,6-dione (254 mg, 0.52 mmol) and NaOAc (51 mg, 0.63 mmol) in MeOH (10 mL) was added NaBH 3 CN (66 mg, 1.05 mmol).
  • Step 4 Preparation of (S)-5-(4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)piperazin-1- yl)pentanoic acid [0223] To a solution of tert-butyl (S)-5-(4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5- yl)piperazin-1-yl)pentanoate (200 mg, 0.41 mmol) in DCM (3 mL) was added TFA (1 mL). The mixture was stirred at room temperature for 3 hours.
  • Step 5 Preparation of N-(4-(4-amino-1-(1-(5-(4-(2-((S)-2,6-dioxopiperidin-3-yl)-1-oxoisoindolin -5- yl)piperazin-1-yl)pentanoyl)pyrrolidin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)benzyl)-5-fluoro-2- methoxybenzamide [0224] To a solution of (S)-5-(4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)piperazin-1- yl)penta noic acid (177 mg, 0.41 mmol), N-(4-(4-amino-1-(1-(5-(4-(2-((S)-2,6-dioxopiperidin-3-yl)-1-oxoiso
  • Example 56 Preparation of N-(4-(4-amino-1-(1-(6-((4-(2-((S)-2,6-dioxopiperidin-3-yl)-1- oxoisoindolin-5-yl)piperazin-1-yl)methyl)pyridin-3-yl)pyrrolidin-3-yl)-1H-pyrazolo[3,4- d]pyrimidin-3-yl)benzyl)-5-fluoro-2-methoxybenzamide (Compound 58) Step 1: Preparation of tert-butyl 3-(tosyloxy)pyrrolidine-1-carboxylate [0225] To a solution of tert-butyl (3-hydroxypyrrolidin-1-yl) formate (5 g, 26.6 mmol) in pyridine (50 mL) was added TsCl (6.1 g, 31.9 mmol) at room temperature.
  • Step 2 Preparation of tert-butyl 3-(4-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl) -1H- pyrazolo[3,4-d]pyrimidin-1-yl)pyrrolidine-1-carboxylate
  • tert-butyl (3- ⁇ [(4-methylbenzene)sulfonyl]oxy ⁇ pyrrolidin-1-yl) formate (2 g, 5.84 mmol)
  • DMF 20 mL
  • N-[(4- ⁇ 4-amino-1H- pyrazolo[3,4-d]pyrimidin-3-yl ⁇ phenyl)methyl]-5-fluoro-2-methoxybenzamide 2.3 g, 5.84 mmol
  • Cs 2 CO 3 (3.8 g, 11.68 mmol).
  • Step 3 Preparation of N-(4-(4-amino-1-(pyrrolidin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)benzyl)-5- fluoro-2-methoxybenzamide
  • Step 5 Preparation of N-(4-(4-amino-1-(1-(6-(dimethoxymethyl)pyridin-3-yl)pyrrolidin-3-yl)-1H- pyrazolo[3,4-d]pyrimidin-3-yl)benzyl)-5-fluoro-2-methoxybenzamide
  • N-( ⁇ 4-[4-amino-1-(pyrrolidin-3-yl)pyrazolo[3,4-d]pyrimidin-3- yl]phenyl ⁇ methyl)-5-fluoro-2-methoxybenzamide 160 mg, 0.35 mmol
  • toluene 10 mL
  • 5-bromo-2-(dimethoxymethyl)pyridine 123 mg, 0.53 mmol
  • BINAP 130 mg, 0.21 mmol
  • t-BuONa 67 mg, 0.7 mmol
  • Pd2(dba)3 96 mg
  • Step 6 Preparation of N-(4-(4-amino-1-(1-(6-formylpyridin-3-yl)pyrrolidin-3-yl)-1H-pyrazolo [3,4- d]pyrimidin-3-yl)benzyl)-5-fluoro-2-methoxybenzamide
  • Step 7 Preparation of N-(4-(4-amino-1-(1-(6-((4-(2-((S)-2,6-dioxopiperidin-3-yl)-1-oxoisoind olin-5- yl)piperazin-1-yl)methyl)pyridin-3-yl)pyrrolidin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)benzyl)-5- fluoro-2-methoxybenzamide [0231] To a solution of N-(4-(4-amino-1-(1-(6-formylpyridin-3-yl)pyrrolidin-3-yl)-1H- pyrazolo[3,4-d]pyrimidin-3-yl)benzyl)-5-fluoro-2-methoxybenzamide (21 mg, 0.03 mmol) in MeOH/DMF/ HOAc (5 mL, 2:1:0.02) was added TEA (7.5
  • Example 57 Preparation of (S)-N-(4-(4-amino-1-(6-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-1- oxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)pyridin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin- 3-yl)benzyl)-5-fluoro-2-methoxybenzamide (Compound 59)
  • Step 1 Preparation of (1-(5-iodopyridin-2-yl)piperidin-4-yl)methanol
  • 2-fluoro-5-iodopyridine 2 g, 9.0 mmol
  • piperidin-4-ylmethanol 1.2 g,10.8 mmol
  • potassium carbonate 3.0 mmol
  • the reaction mixture was stirred at 100 °C for 2 hours.
  • Step 2 Preparation of 1-(5-iodopyridin-2-yl)piperidine-4-carbaldehyde [0233] To a solution of [1-(5-iodopyridin-2-yl)piperidin-4-yl]methanol (1 g, 3.1 mmol) in DCM (50 mL) stirred under nitrogen at 25 °C was added Dess-Martin periodinane (2.0 g, 4.6 mmol) in portions. The reaction mixture was stirred at 25 °C for 1 hour.
  • Step 3 Preparation of 2-(4-(dimethoxymethyl)piperidin-1-yl)-5-iodopyridine
  • TsOH 40 mg, 0.2 mmol
  • the reaction mixture was stirred at 100 °C for 2 hours.
  • the reaction mixture was evaporated in vacuum to give a crude product.
  • Step 5 Preparation of N-(4-(4-amino-1-(6-(4-formylpiperidin-1-yl)pyridin-3-yl)-1H-pyrazolo [3,4- d]pyrimidin-3-yl)benzyl)-5-fluoro-2-methoxybenzamide
  • a solution of N- ⁇ [4-(4-amino-1- ⁇ 6-[4-(dimethoxymethyl)piperidin-1-yl]pyridin-3- yl ⁇ pyrazolo [3,4-d]pyrimidin-3-yl)phenyl]methyl ⁇ -5-fluoro-2-methoxybenzamide (15 mg, 0.023 mmol) in THF/H 2 SO 4 (2N) (5 mL, 1:1) was stirred at 70 °C for 1 hour.
  • Step 6 Preparation of (S)-N-(4-(4-amino-1-(6-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindo lin-5- yl)piperazin-1-yl)methyl)piperidin-1-yl)pyridin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl) benzyl)-5- fluoro-2-methoxybenzamide [0237] To a solution of N-[(4- ⁇ 4-amino-1-[6-(4-formylpiperidin-1-yl)pyridin-3- yl]pyrazolo[3,4-d]pyrimi din-3-yl ⁇ phenyl)methyl]-5-fluoro-2-methoxybenzamide (15 mg,0.025 mmol), (3S)-3-[1-oxo-5-(piperazin-1-yl)-3H-is
  • Example 58 Preparation of N-(4-(4-amino-1-(1-(4-((4-(2-((S)-2,6-dioxopiperidin-3-yl)-1- oxoisoindolin-5-yl)piperazin-1-yl)methyl)phenyl)pyrrolidin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-3- yl)benzyl)-5-fluoro-2-methoxybenzamide (Compound 60) Step 1: Preparation of N-(4-(4-amino-1-(1-(4-formylphenyl)pyrrolidin-3-yl)-1H-pyrazolo[3,4-d] pyrimidin-3-yl)benzyl)-5-fluoro-2-methoxybenzamide [0238] To a solution of N-( ⁇ 4-[4-amino-1-(pyrrolidin-3-yl)pyrazolo[3,4
  • the reaction mixture was stirred at 80 °C for 12 hours.
  • the reaction mixture was poured into water (100 mL) and extracted with EA (100 mL ⁇ 2).
  • the combined organic layers were washed with water, brine, dried over Na 2 SO 4 then concentrated under vacuum to give a crude product.
  • Step 2 Preparation of N-(4-(4-amino-1-(1-(4-((4-(2-((S)-2,6-dioxopiperidin-3-yl)-1-oxoisoindo lin-5- yl)piperazin-1-yl)methyl)phenyl)pyrrolidin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)benzyl) -5-fluoro-2- methoxybenzamide [0239] To a solution of N-[(4- ⁇ 4-amino-1-[1-(4-formylphenyl)pyrrolidin-3-yl]pyrazolo[3,4- d]pyrimidin-3-yl ⁇ phenyl)methyl]-5-fluoro-2-methoxybenzamide (100 mg, 0.18 mmol) in MeOH/DMF/HOAc (12 mL, 2: 1: 0.06) stirred at room temperature was added (S
  • Example 59 Preparation of (S)-N-(4-(4-amino-1-(1-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-1- oxoisoindolin-5-yl)piperazin-1-yl)methyl)phenyl)azetidin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-3- yl)benzyl)-5-fluoro-2-methoxybenzamide (Compound 61) Step 1: Preparation of N-(4-(4-amino-1-(1-(4-formylphenyl)azetidin-3-yl)-1H-pyrazolo[3,4-d]py rimidin- 3-yl)benzyl)-5-fluoro-2-methoxybenzamide [0240] The mixture of N-(4-(4-amino-1-(azetidin-3-yl)-1H-pyr
  • Step 2 Preparation of (S)-N-(4-(4-amino-1-(1-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindo lin-5- yl)piperazin-1-yl)methyl)phenyl)azetidin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)benzyl)-5-fluoro-2- methoxybenzamide [0241] To a solution of N-(4-(4-amino-1-(1-(4-formylphenyl)azetidin-3-yl)-1H-pyrazolo[3,4- d]pyrimi din-3-yl)benzyl)-5-fluoro-2-methoxybenzamide (20 mg, 80 % purity, 0.029 mmol) in MeOH/ DMF (2: 1, 3 mL) stirred at room temperature was added (S)-3
  • Step 1 Preparation of tert-butyl (S)-4-((4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)pi perazin-1- yl)methyl)benzoate
  • (S)-3-(1-oxo-5-(piperazin-1-yl)isoindolin-2-yl)piperidine-2,6-dione 100 mg, 0.2 mmol
  • TEA 41.51 mg, 0.4 mmol
  • Step 2 Preparation of (S)-4-((4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)piperazin-1- yl)methyl)benzoic acid
  • (S)-4-((4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)piperazin-1- yl)methyl)benzoate 100 mg, 90 % purity, 0.17 mmol ) in DCM (3 mL) and TFA (1 mL) was stirred at room temperature for 2 hours.
  • Step 3 Preparation of tert-butyl 3-(4-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl) phenyl) -1H- pyrazolo[3,4-d]pyrimidin-1-yl)azetidine-1-carboxylate [0244] To a solution of N-(4-(4-amino-1H-pyrazolo[3,4-d]pyrimidin-3-yl)benzyl)-5-fluoro-2- methoxy benzamide (500 mg, 1.27 mmol) in DMF (10 ml) was added tert-butyl-3-(tosyloxy)azetidine-1- carboxylate (502 mg, 1.52 mmol) and Cs 2 CO 3 (1.24 g, 3.82
  • Step 4 Preparation of N-(4-(4-amino-1-(azetidin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)benzyl) -5- fluoro-2-methoxybenzamide
  • Step 5 Preparation of (S)-N-(4-(4-amino-1-(1-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindo lin-5- yl)piperazin-1-yl)methyl)benzoyl)azetidin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)benzyl) -5-fluoro-2- methoxybenzamide [0246] To a solution of 4-[(4- ⁇ 2-[(3S)-2,6-dioxopiperidin-3-yl]-1-oxo-3H-isoindol-5- yl ⁇ piperazin-1-yl)methyl]benzoic acid (44 mg, 80 % purity, 0.07 mmol) in THF (5 mL) was added N-( ⁇ 4- [4-amino-1-(azetidin-3-yl)
  • Example 61 Preparation of (N-(4-(4-amino-1-(1-(4-((4-(2-((S)-2,6-dioxopiperidin-3-yl)-1- oxoisoindolin-5-yl)piperazin-1-yl)methyl)benzoyl)pyrrolidin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-3- yl)benzyl)-5-fluoro-2-methoxybenzamide (Compound 63) Step 1: Preparation of (N-(4-(4-amino-1-(1-(4-((4-(2-((S)-2,6-dioxopiperidin-3-yl)-1-oxoisoindol in-5- yl)piperazin-1-yl)methyl)benzoyl)pyrrolidin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)
  • Example 62 Preparation of N-(4-(4-amino-1-(1-(6-(4-(2-((S)-2,6-dioxopiperidin-3-yl)-1- oxoisoindolin-5-yl)piperazin-1-yl)hexanoyl)pyrrolidin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-3- yl)benzyl)-5-fluoro-2-methoxybenzamide (Compound 64) Step 1: Preparation of (S)-6-(4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)piperazin-1-yl)hexanoic acid [0248] A suspension of 6-bromohexanoic acid (100 mg, 0.51 mmol), (S)-3-(1-oxo-5- (piperazin-1-yl)isoindolin-2-yl
  • Example 63 Preparation of N-(4-(4-amino-1-(4-(3-((4-(2-((S)-2,6-dioxopiperidin-3-yl)-1- oxoisoindolin-5-yl)piperazin-1-yl)methyl)pyrrolidin-1-yl)-3-fluorophenyl)-1H-pyrazolo[3,4- d]pyrimidin-3-yl)benzyl)-5-fluoro-2-methoxybenzamide (Compound 65) Step 1: Preparation of (1-(2-fluoro-4-nitrophenyl)pyrrolidin-3-yl)methanol [0250] To a solution of 1,2-difluoro-4-nitrobenzene (2 g, 12.57 mmol) in CH 3 CN (5 mL) was added pyrrolidin-3-ylmethanol (1.9 g, 13.83 mmol) and DIEA (4.9 g, 37.71 mmol).
  • Step 2 Preparation of (1-(4-amino-2-fluorophenyl)pyrrolidin-3-yl)methanol [0251] To a solution of (1-(2-fluoro-4-nitrophenyl)pyrrolidin-3-yl)methanol (1.8 g, 7.49 mmol) in MeOH (20 mL) was added Pd/C (180 mg, 10%).
  • Step 3 Preparation of (1-(2-fluoro-4-iodophenyl)pyrrolidin-3-yl)methanol [0252] To a solution of (1-(4-amino-2-fluorophenyl)pyrrolidin-3-yl)methanol (1.3 g, 6.1 mmol) in CH 3 CN (30 mL) was added 1.9 mL con.
  • Step 4 Preparation of 1-(2-fluoro-4-iodophenyl)pyrrolidine-3-carbaldehyde [0253] To a solution of oxalyl chloride (1.19 g, 9.34 mmol) in DCM (20 mL) was added DMSO (1.46 g, 18.68 mmol) at -78 °C. The reaction mixture was stirred at -78°C for 15 minutes then (1- (2-fluoro-4-iodophenyl)pyrrolidin-3-yl)methanol (1.5 g, 4.67 mmol) was added. The reaction mixture was stirred at -78 °C for the other 15 minutes.
  • Step 5 Preparation of 3-(dimethoxymethyl)-1-(2-fluoro-4-iodophenyl)pyrrolidine [0254] To a solution of 1-(2-fluoro-4-iodophenyl)pyrrolidine-3-carbaldehyde (1.2 g, 3.76 mmol) in MeOH (20 mL) was added trimethoxymethane (600 mg, 5.46 mmol) and PTSA (97 mg, 1.36 mmol). The reaction was stirred at 60 °C for 12 hours. The solvent was removed in vacuum. The residue was dissolved in EA (20 mL), washed with NaHCO 3 solution and dried over Na 2 SO 4 .
  • Step 7 Preparation of N-(4-(4-amino-1-(3-fluoro-4-(3-formylpyrrolidin-1-yl)phenyl)-1H-pyrazo lo[3,4- d]pyrimidin-3-yl)benzyl)-5-fluoro-2-methoxybenzamide
  • N-(4-(4-amino-1-(4-(3-(dimethoxymethyl)pyrrolidin-1-yl)-3- fluorophenyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)benzyl)-5-fluoro-2-methoxybenzamide 80 mg, 60 % purity, 0.076 mmol
  • THF 2 mL
  • H 2 SO 4 4 mL , 3 M in water
  • Step 8 Preparation of N-(4-(4-amino-1-(4-(3-((4-(2-((S)-2,6-dioxopiperidin-3-yl)-1-oxoisoindo lin-5- yl)piperazin-1-yl)methyl)pyrrolidin-1-yl)-3-fluorophenyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)benzyl)-5- fluoro-2-methoxybenzamide [0257] To a solution of (S)-3-(1-oxo-5-(piperazin-1-yl)isoindolin-2-yl)piperidine-2,6-dione benzenesulfonic acid (11.26 mg, 0.034 mmol) in DMF (1 mL) and MeOH (1 mL) was added TEA (0.2 mL).
  • Example 64 Preparation of N-(4-(4-amino-1-(6-(3-((4-(2-((S)-2,6-dioxopiperidin-3-yl)-1- oxoisoindolin-5-yl)piperazin-1-yl)methyl)pyrrolidin-1-yl)pyridin-3-yl)-1H-pyrazolo[3,4- d]pyrimidin-3-yl)benzyl)-5-fluoro-2-methoxybenzamide (Compound 66) Step 1: Preparation of (1-(5-iodopyridin-2-yl)pyrrolidin-3-yl)methanol [0258] To a solution of 2-fluoro-5-iodopyridine (2 g, 9 mmol) in DMF (20 mL) was added pyrrolidin-3-ylmethanol (1.09 g, 10.8 mmol) and potassium carbonate (3.73 g, 2.7 mmol).
  • Step 2 Preparation of 1-(5-iodopyridin-2-yl)pyrrolidine-3-carbaldehyde [0259] To a solution of [1-(5-iodopyridin-2-yl)pyrrolidin-3-yl]methanol (2 g, 6.6 mmol) in DCM (30 mL) stirred under nitrogen at 0 °C was added Dess-Martin periodinane (4.2 g, 9.9 mmol) in portions. The reaction mixture was stirred at room temperature for 2 hours. The reaction was quenched by adding water (10 mL). The organic phase was washed with brine and dried over Na 2 SO 4 .
  • Step 3 Preparation of 2-(3-(dimethoxymethyl)pyrrolidin-1-yl)-5-iodopyridine [0260] To a solution of 1-(5-iodopyridin-2-yl)pyrrolidine-3-carbaldehyde (1.5 g, 5.0 mmol) in trimethoxy methane (20 mL) stirred under nitrogen at 25 °C was added TsOH (90 mg, 0.5 mmol). The reaction was stirred at 100 °C for 2 hours.
  • Step 4 Preparation of N-(4-(4-amino-1-(6-(3-(dimethoxymethyl)pyrrolidin-1-yl)pyridin-3-yl)-1H- pyrazolo[3,4-d]pyrimidin-3-yl)benzyl)-5-fluoro-2-methoxybenzamide
  • 2-(3-(dimethoxymethyl)pyrrolidin-1-yl)-5-iodopyridine 120 mg, 0.34 mmol
  • N-(4-(4-amino-1H-pyrazolo[3,4-d]pyrimidin-3-yl)benzyl)-5-fluoro-2- methoxybenzamide (135 mg, 0.34 mmol), Cs 2 CO 3 (336.8 mg, 1.03 mmol), Copper(I) iodide (65.3 mg, 0.34 mmol) and N 1 ,N 1 -Dimethylcyclohex
  • Step 5 Preparation of N-(4-(4-amino-1-(6-(3-formylpyrrolidin-1-yl)pyridin-3-yl)-1H-pyrazolo [3,4- d]pyrimidin-3-yl)benzyl)-5-fluoro-2-methoxybenzamide
  • a solution of N-(4-(4-amino-1-(6-(3-(dimethoxymethyl)pyrrolidin-1-yl)pyridin-3-yl)- 1H-pyrazolo[3,4-d]pyrimidin-3-yl)benzyl)-5-fluoro-2-methoxybenzamide (15 mg, 0.025 mmol) in H 2 SO 4 / H 2 O/THF (1 mL, 1/3/2) was stirred under nitrogen at 70 °C for 1 hour.
  • Step 6 Preparation of N-(4-(4-amino-1-(6-(3-((4-(2-((S)-2,6-dioxopiperidin-3-yl)-1-oxoisoindo lin-5- yl)piperazin-1-yl)methyl)pyrrolidin-1-yl)pyridin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl) benzyl)-5- fluoro-2-methoxybenzamide [0263] To a solution of N-(4-(4-amino-1-(6-(3-formylpyrrolidin-1-yl)pyridin-3-yl)-1H- pyrazolo[3,4-d]pyrimidin-3-yl)benzyl)-5-fluoro-2-methoxybenzamide (12 mg,0.02 mmol) in MeOH/DMF/ HOAc (2 mL, 2:1:0.02) was added 2-(2,
  • Step 2 Preparation of 6-(4-(3-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)-4-methoxybenzoyl)piperazin-1- yl)hexanoic acid
  • TFA 1,3-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)-4- methoxybenzoyl
  • Step 3 Preparation of 1-(5-(4-(6-(4-((5-(2-chloro-4-phenoxybenzoyl)-7H-pyrrolo[2,3-d]pyrimidin-4- yl)amino)piperidin-1-yl)-6-oxohexyl)piperazine-1-carbonyl)-2-methoxyphenyl)dihydropy rimidine- 2,4(1H,3H)-dione [0266] To a solution of 6-(4-(3-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)-4- methoxybenzoyl)piperazin-1-yl)hexanoic acid (80 mg, crude) in DCM (5 mL) was added HATU (102 mg, 0.27 mmol) and TEA (54 mg, 0.54 mmol).
  • Example 66 Preparation of 1-(5-(4-(5-(4-((5-(2-chloro-4-phenoxybenzoyl)-7H-pyrrolo[2,3- d]pyrimidin-4-yl)amino)piperidin-1-yl)-5-oxopentyl)piperazine-1-carbonyl)-2- methoxyphenyl)dihydropyrimidine-2,4(1H,3H)-dione (Compound 72) Step 1: Preparation of tert-butyl 5-(4-(3-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)-4-methoxy benzoyl)piperazin-1-yl)pentanoate [0267] A solution of tert-butyl 5-bromopentanoate (380 mg, 1.60 mmol), 1-(2-methoxy-5- (piperazine-1-carbonyl)phenyl)dihydropyrim
  • Step 2 Preparation of 5-(4-(3-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)-4-methoxybenzoyl) piperazin-1- yl)pentanoic acid
  • Step 2 Preparation of tert-butyl 2-([1,4'-bipiperidin]-4-yl)acetate
  • benzyl 4-(2-(tert-butoxy)-2-oxoethyl)-[1,4'-bipiperidine]-1'-carboxylate 850 mg, 80 % purity, 1.63 mmol
  • Pd/C 100 mg
  • the mixture stirred at 20 °C for overnight under H 2 .
  • the catalyst was filtered off.
  • the solution was concentrated in vacuum to afford the title product (320 mg, 90 % purity, 62 % yield) as a white solid.
  • Step 3 Preparation of tert-butyl 2-(1'-(3-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)-4-methoxy benzoyl)- [1,4'-bipiperidin]-4-yl)acetate
  • Step 4 Preparation of 2-(1'-(3-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)-4-methoxybenzoyl)-[1,4'- bipiperidin]-4-yl)acetic acid [0273] A solution of tert-butyl 2-(1'-(3-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)-4- methoxybenzoyl)-[1,4'-bipiperidin]-4-yl)acetate (30 mg, 0.056 mmol) in DCM (5 mL) and TFA (2 mL) was stirred at room temperature for 2 hours.
  • Step 5 Preparation of 1-(5-(4-(2-(4-((5-(2-chloro-4-phenoxybenzoyl)-7H-pyrrolo[2,3-d]pyrimidin-4- yl)amino)piperidin-1-yl)-2-oxoethyl)-[1,4'-bipiperidine]-1'-carbonyl)-2-methoxyphenyl)di hydropyrimidine-2,4(1H,3H)-dione [0274] A solution of 2-(1'-(3-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)-4-methoxybenzoyl)- [1,4'-bipiper idin]-4-yl)acetic acid (30 mg, 0.056 mmol), (2-chlor
  • Example 68 Preparation of 1-(5-(4-((1-(4-((5-(2-chloro-4-phenoxybenzoyl)-7H-pyrrolo[2,3- d]pyrimidin-4-yl)amino)-2-fluorophenyl)piperidin-4-yl)methyl)piperazine-1-carbonyl)-2- methoxyphenyl)dihydropyrimidine-2,4(1H,3H)-dione (Compound 74)
  • Step 1 Preparation of 1-(4-((5-(2-chloro-4-phenoxybenzoyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2- fluorophenyl)piperidine-4-carbaldehyde
  • (2-chloro-4-phenoxyphenyl)(4-((4-(4-(dimethoxymethyl)piperidin-1- yl)-3-fluorophenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-5-yl)methanone 200 mg, 0.33 mmol
  • sulfuric acid (2M, 5 mL, 10 mmol).
  • Step 2 Preparation of 1-(5-(4-((1-(4-((5-(2-chloro-4-phenoxybenzoyl)-7H-pyrrolo[2,3-d]pyrimidin-4- yl)amino)-2-fluorophenyl)piperidin-4-yl)methyl)piperazine-1-carbonyl)-2- methoxyphenyl)dihydropyrimidine-2,4(1H,3H)-dione [0276] To a solution of 1-(4-((5-(2-chloro-4-phenoxybenzoyl)-7H-pyrrolo[2,3-d]pyrimidin-4- yl)amino)-2-fluorophenyl)piperidine-4-carbaldehyde (90 mg, 0.16 mmol), 1-(2-methoxy-5-(piperazine-1- carbonyl)phenyl)dihydropyrimidine-2,4(1H,3H)-dione hydrochloride
  • Example 69 Preparation of 1-(5-(4-((1-(4-((5-(2-chloro-4-phenoxybenzoyl)-7H-pyrrolo[2,3- d]pyrimidin-4-yl)amino)-2-fluorophenyl)piperidin-4-yl)methyl)-1,4-diazepane-1-carbonyl)-2- methoxyphenyl)dihydropyrimidine-2,4(1H,3H)-dione (Compound 75)
  • Step 1 Preparation of tert-butyl 4-(3-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)-4-methoxyben zoyl)-1,4- diazepane-1-carboxylate [0277] To a solution of 3-(2,4-dioxo-1,3-diazinan-1-yl)-4-methoxybenzoic acid (500 mg, 1.89 mmol) in DMF (5 mL) was added HATU (862 mg, 2.268 mmol), DIEA (489 mg, 3.78 mmol) and tert- butyl (1,4-diazepan-1-yl)formate (380 mg, 1.89 mmol) at room temperature.
  • HATU 862 mg, 2.268 mmol
  • DIEA 489 mg, 3.78 mmol
  • tert- butyl (1,4-diazepan-1-yl)formate 380
  • Step 2 Preparation of 1-(5-(1,4-diazepane-1-carbonyl)-2-methoxyphenyl)dihydropyrimidine-2,4(1H,3H)- dione
  • a solution of tert-butyl (4- ⁇ [3-(2,4-dioxo-1,3-diazinan-1-yl)-4- methoxyphenyl]carbonyl ⁇ -1,4-diazepan-1-yl)formate (1 g) in TFA/DCM (1:5, 12 mL) was stirred at room temperature for 2 hours. The solution was concentrated in vacuum. The residue was dissolved in DCM (50 mL), washed with saturated sodium bicarbonate solution and brine.
  • Step 3 Preparation of 1-(5-(4-((1-(4-((5-(2-chloro-4-phenoxybenzoyl)-7H-pyrrolo[2,3-d]pyrimidin-4- yl)amino)-2-fluorophenyl)piperidin-4-yl)methyl)-1,4-diazepane-1-carbonyl)-2- methoxyphenyl)dihydropyrimidine-2,4(1H,3H)-dione [0279] To a solution of 1-(4-((5-(2-chloro-4-phenoxybenzoyl)-7H-pyrrolo[2,3-d]pyrimidin-4- yl)amino)-2-fluorophenyl)piperidine-4-carbaldehyde (80 mg, 0.14
  • Example 70 Preparation of 1-(5-(4-(2-(1-(4-((5-(2-chloro-4-phenoxybenzoyl)-7H-pyrrolo[2,3- d]pyrimidin-4-yl)amino)-2-fluorophenyl)piperidin-4-yl)ethyl)piperazine-1-carbonyl)-2- methoxyphenyl)dihydropyrimidine-2,4(1H,3H)-dione (Compound 76) [0280] A solution of 2-(1-(4-((5-(2-chloro-4-phenoxybenzoyl)-7H-pyrrolo[2,3-d]pyrimidin-4- yl)amino)-2-fluorophenyl)piperidin-4-yl)acetaldehyde (140 mg, 0.24 mmol), 1-(2-methoxy-5-(piperazine- 1-carbonyl)phenyl)dihydropyrimidine-2,4(
  • Step 1 Preparation of (R)-1-(5-(4-(2-(3-((5-(2-chloro-4-phenoxybenzoyl)-7H-pyrrolo[2,3-d]pyri midin-4- yl)amino)piperidin-1-yl)-2-oxoethyl)-[1,4'-bipiperidine]-1'-carbonyl)-2-methoxyphenyl) dihydropyrimidine-2,4(1H,3H)-dione [0281] A solution of 2-(1'-(3-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)-4-methoxybenzoyl)- [1,4'-bipiperi din]-4-yl)acetic acid (70 mg, 0.15 mmol), (R)-(2-chloro-4-phenoxyphenyl)(4-(piperidin-3- ylamino)-7H-pyrrolo[2,
  • Example 72 Preparation of 1-(5-(4-(7-(4-((5-(2-chloro-4-phenoxybenzoyl)-7H-pyrrolo[2,3- d]pyrimidin-4-yl)amino)piperidin-1-yl)-7-oxoheptyl)piperazine-1-carbonyl)-2- methoxyphenyl)dihydropyrimidine-2,4(1H,3H)-dione (Compound 78) Step 1: Preparation of 7-bromoheptanoyl chloride [0282] A solution of 7-bromoheptanoic acid (1 g, 4.8 mmol) in thionyl chloride (20 mL) was stirred at 70 °C for 5 hours.
  • Step 3 Preparation of 1-(5-(4-(7-(4-((5-(2-chloro-4-phenoxybenzoyl)-7H-pyrrolo[2,3-d]pyrimidin-4- yl)amino)piperidin-1-yl)-7-oxoheptyl)piperazine-1-carbonyl)-2-methoxyphenyl)dihydropy rimidine- 2,4(1H,3H)-dione [0284] To a solution of 7-bromo-1-(4-((5-(2-chloro-4-phenoxybenzoyl)-7H-pyrrolo[2,3- d]pyrimidin-4-yl)amino)piperidin-1-yl)heptan-1-one (60 mg, 0.09 mmol), 1- ⁇ 2-methoxy-5-[(piperazin-1- yl)carbonyl] phenyl ⁇ -1,3-diazinane (31.20 mg, 0.09
  • Example 73 Preparation of 1-(5-(4-(4-(4-(4-((5-(2-chloro-4-phenoxybenzoyl)-7H-pyrrolo[2,3- d]pyrimidin-4-yl)amino)piperidine-1-carbonyl)benzyl)-1,4-diazepane-1-carbonyl)-2- methoxyphenyl)dihydropyrimidine-2,4(1H,3H)-dione (Compound 79)
  • Step 1 Preparation of tert-butyl 4-((4-(3-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)-4-methoxy benzoyl)- 1,4-diazepan-1-yl)methyl)benzoate [0285] To a solution of 1-(5-(1,4-diazepane-1-carbonyl)-2-methoxyphenyl)dihydropyrimidine- 2,4(1H, 3H)-dione (80 mg, 0.23 mmol) in DMF (5 mL) was added tert-butyl 4-(bromomethyl)benzoate (69 mg, 0.25 mmol) and K 2 CO 3 (64 mg, 0.46 mmol).
  • Step 2 Preparation of 4-((4-(3-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)-4-methoxybenzoyl)-1,4- diazepan-1-yl)methyl)benzoic acid [0286] To a solution of tert-butyl 4-((4-(3-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)-4- methoxybenzoyl)-1,4-diazepan-1-yl)methyl)benzoate (72 mg, 0.13 mmol) in DCM (3 mL) was added TFA (1 mL). The reaction was stirred at room temperature for 2 hours.
  • Step 3 Preparation of 1-(5-(4-(4-(4-((5-(2-chloro-4-phenoxybenzoyl)-7H-pyrrolo[2,3-d]pyrimi din-4- yl)amino)piperidine-1-carbonyl)benzyl)-1,4-diazepane-1-carbonyl)-2-methoxyphenyl)dihy dropyrimidine-2,4(1H,3H)-dione [0287] To a solution of 4-((4-(3-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)-4-methoxybenzoyl)- 1,4-diaze pan-1-yl)methyl)benzoic acid (80 mg, crude) in DCM (5 mL) was added HA
  • Example 74 Preparation of 1-(5-(4-(4-(4-(4-((5-(2-chloro-4-phenoxybenzoyl)-7H-pyrrolo[2,3- d]pyrimidin-4-yl)amino)piperidine-1-carbonyl)benzyl)piperazine-1-carbonyl)-2- methoxyphenyl)dihydropyrimidine-2,4(1H,3H)-dione (Compound 80) Step 1: Preparation of tert-butyl 4-((4-(3-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)-4-methoxy benzoyl)piperazin-1-yl)methyl)benzoate [0288] A mixture of tert-butyl 4-(bromomethyl)benzoate (150 mg, 0.55 mmol ), 1-(2- methoxy-5-(piperazine-1-carbonyl)phenyl)dihydr
  • Step 2 Preparation of 4-((4-(3-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)-4-methoxybenzoyl)pi perazin-1- yl)methyl)benzoic acid [0289] To a solution of tert-butyl 4-((4-(3-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)-4- methoxybenzoyl) piperazin-1-yl)methyl)benzoate ( 160 mg) in DCM (20 mL) was added TFA (6 mL).
  • Step 3 Preparation of 1-(5-(4-(4-(4-(4-((5-(2-chloro-4-phenoxybenzoyl)-7H-pyrrolo[2,3-d]pyrimi din-4- yl)amino)piperidine-1-carbonyl)benzyl)piperazine-1-carbonyl)-2-methoxyphenyl)dihydro pyrimidine- 2,4(1H,3H)-dione [0290] A solution of 4-((4-(3-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)-4- methoxybenzoyl)piperazin-1-yl)methyl)benzoic acid (83 mg, purity: 70 %, 0.12 mmol), (2-chlor
  • Example 75 Preparation of (S)-N-(4-(4-amino-1-(4-(3-((4-(2-(2,6-dioxopiperidin-3-yl)-1- oxoisoindolin-5-yl)piperazin-1-yl)methyl)azetidin-1-yl)-3-fluorophenyl)-1H-pyrazolo[3,4- d]pyrimidin-3-yl)benzyl)-5-fluo ro-2-methoxybenzamide (Compound 85)
  • Step 1 Preparation of (1-(2-fluoro-4-nitrophenyl)azetidin-3-yl)methanol [0291] The mixture of 1,2-difluoro-4-nitrobenzene (2.0 g, 12.6 mmol), azetidin-3-ylmethanol (1.3 g, 15.1 mmol) and DIEA (4.9 g, 37.8 mmol) in ACN (15 mL)
  • Step 2 Preparation of (1-(4-amino-2-fluorophenyl)azetidin-3-yl)methanol [0292] To a solution of (1-(2-fluoro-4-nitrophenyl)azetidin-3-yl)methanol (2.5 g, 11.1 mmol) in MeOH (30 mL) was added Pd/C (0.25 g, 10 %). The mixture was stirred at room temperature under H 2 at 1 atm for overnight.
  • Step 3 Preparation of (1-(2-fluoro-4-iodophenyl)azetidin-3-yl)methanol [0293] To a solution of (1-(4-amino-2-fluorophenyl)azetidin-3-yl)methanol (2.0 g, 10.2 mmol) in ACN (40 mL) and con. HCl (3.5 mL) was added a solution of NaNO 2 (0.91 g, 13.2 mmol) in water (4 mL) at 0 °C.
  • Step 4 Preparation of 1-(2-fluoro-4-iodophenyl)azetidine-3-carbaldehyde
  • DCM dimethylethyl
  • Dess-Martin periodinane 2.1 g, 4.9 mmol
  • Step 5 Preparation of 3-(dimethoxymethyl)-1-(2-fluoro-4-iodophenyl)azetidine [0295] To a solution of 1-(2-fluoro-4-iodophenyl)azetidine-3-carbaldehyde (800 mg, 2.6 mmol) in MeOH (10 mL) was added acetyl chloride (310 mg, 3.9 mmol) stirred under nitrogen at 0 °C. The mixture was stirred at 25 °C for 2 hours. The reaction was quenched by adding TEA (1 mL).
  • Step 7 Preparation of N-(4-(4-amino-1-(3-fluoro-4-(3-formylazetidin-1-yl)phenyl)-1H-pyrazolo [3,4- d]pyrimidin-3-yl)benzyl)-5-fluoro-2-methoxybenzamide
  • N-(4-(4-amino-1-(4-(3-(dimethoxymethyl)azetidin-1-yl)-3- fluorophenyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)benzyl)-5-fluoro-2-methoxybenzamide 200 mg, 80 % purity, 0.26 mmol
  • THF H 2 O:H 2 SO 4 (6 mL, 2:3:1).
  • Step 8 Preparation of (S)-N-(4-(4-amino-1-(4-(3-((4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindo lin-5- yl)piperazin-1-yl)methyl)azetidin-1-yl)-3-fluorophenyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl) benzyl)-5- fluoro-2-methoxybenzamide [0298] To a solution of N-(4-(4-amino-1-(3-fluoro-4-(3-formylazetidin-1-yl)phenyl)-1H- pyrazolo[3,4-d]pyrimidin-3-yl)benzyl)-5-fluoro-2-methoxybenzamide (100 mg, 0.17 mmol), (S)-3-(1- oxo-5-(piperazin-1-
  • Example 76 Preparation of N-(4-(4-amino-1-(1-(5-((4-(2-((S)-2,6-dioxopiperidin-3-yl)-1- oxoisoindolin-5-yl)piperazin-1-yl)methyl)pyridin-2-yl)pyrrolidin-3-yl)-1H-pyrazolo[3,4- d]pyrimidin-3-yl)benzyl)-5-fluoro-2-methoxybenzamide (Compound 92) Step 1: Preparation of N-(4-(4-amino-1-(1-(5-formylpyridin-2-yl)pyrrolidin-3-yl)-1H-pyrazolo [3,4- d]pyrimidin-3-yl)benzyl)-5-fluoro-2-methoxybenzamide [0299] To a solution of N-( ⁇ 4-[4-amino-1-(pyrrolidin-3-y
  • Step 2 Preparation of N-(4-(4-amino-1-(1-(5-((4-(2-((S)-2,6-dioxopiperidin-3-yl)-1-oxoisoindo lin-5- yl)piperazin-1-yl)methyl)pyridin-2-yl)pyrrolidin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl) benzyl)-5- fluoro-2-methoxybenzamide [0300] To a solution of N-(4-(4-amino-1-(1-(5-formylpyridin-2-yl)pyrrolidin-3-yl)-1H- pyrazolo[3,4-d]pyrimidin-3-yl)benzyl)-5-fluoro-2-methoxybenzamide (130 mg, 0.23 mmol) in MeOH/DMF/ HOAc (12 mL, 2: 1: 0.05,)
  • Example 77 Preparation of N-(4-(4-amino-1-(6-((R)-3-((4-(2-((S)-2,6-dioxopiperidin-3-yl)-1- oxoisoindolin-5-yl)piperazin-1-yl)methyl)pyrrolidin-1-yl)pyridin-3-yl)-1H-pyrazolo[3,4- d]pyrimidin-3-yl)benzyl)-5-fluoro-2-methoxybenzamide (Compound 93) Compound 93 was prepared analogously with the procedure described for compound 66. LC/MS: 878.8 [M+H] + .
  • Example 78 Preparation of N-(4-(4-amino-1-(6-((S)-3-((4-(2-((S)-2,6-dioxopiperidin-3-yl)-1- oxoisoindolin-5-yl) piperazin-1-yl)methyl)pyrrolidin-1-yl)pyridin-3-yl)-1H-pyrazolo[3,4- d]pyrimidin-3-yl)benzyl)-5-fluoro-2-methoxybenzamide (Compound 94)
  • Step 2 Preparation of 4-((5-fluoro-2-methoxybenzamido)methyl)benzoyl chloride [0302] To a solution of 4- ⁇ [(5-fluoro-2-methoxyphenyl)formamido] methyl ⁇ benzoic acid (3.9 g, 12.86 mmol) in DCM (50 mL) stirred at room temperature was added oxalyl chloride (2.2 mL, 25.72 mmol). The reaction mixture was stirred at room temperature for 2 hours. The reaction mixture was concentrated under vacuum to give the title compound (4.0 g, crude) as a brown oil.
  • Step 3 Preparation of N-(4-(2,2-dicyanoacetyl)benzyl)-5-fluoro-2-methoxybenzamide
  • 4- ⁇ [(5-fluoro-2-methoxyphenyl)formamido] methyl ⁇ benzoyl chloride (4 g, crude) and propanedinitrile (960 mg, 14.54 mmol) in acetone (40 mL) stirred at 5 °C was added NaOH (4 mL, 39.26 mmol, 40 %) slowly. The reaction mixture was stirred at room temperature for 2 hours. The mixture was diluted with water (40 mL) and added HCl (5 M) was added to adjust to pH to 2- 3.
  • Step 4 Preparation of N-(4-(2,2-dicyano-1-methoxyvinyl)benzyl)-5-fluoro-2-methoxybenzamide
  • N- ⁇ [4-(2,2-dicyanoacetyl)phenyl]methyl ⁇ -5-fluoro-2- methoxybenzamide (3.14 g, 8.94 mmol) in dioxane (40 mL) stirred at room temperature was added NaHCO 3 (6.0 g, 71.52 mmol) and dimethyl sulfate (8.45 g, 67.05 mmol). The reaction mixture was stirred at 100 °C for 2.5 hours.
  • Step 5 Preparation of N-(4-(5-amino-4-cyano-1H-pyrazol-3-yl)benzyl)-5-fluoro-2-methoxybenzamide
  • N- ⁇ [4-(2,2-dicyano-1-methoxyeth-1-en-1-yl)phenyl]methyl ⁇ -5-fluoro- 2-methoxybenzamide 6.2 g, crude
  • MeOH/Water 20 mL, 2:1
  • Step 6 Preparation of N-(4-(4-amino-1H-pyrazolo[3,4-d]pyrimidin-3-yl)benzyl)-5-fluoro-2- methoxybenzamide
  • N- ⁇ [4-(5-amino-4-cyano-1H-pyrazol-3-yl)phenyl]methyl ⁇ -5-fluoro-2- methoxybenzamide (2.36 g, 6.46 mmol) in formamide (30 mL) was stirred at 160 °C for 2 hours. The mixture was poured into water (100 mL) and extracted with EtOAc (100 mL ⁇ 2). The combined organic layers were washed with brine (200 mL), dried over Na 2 SO 4 and concentrated in vacuum.
  • Step 7 Preparation of (R)-(1-(5-iodopyridin-2-yl)pyrrolidin-3-yl)methanol [0307] To a solution of 2-fluoro-5-iodopyridine (3 g, 13.45 mmol) in DMF (30 mL) stirred at room temperature was added (3R)-pyrrolidin-3-ylmethanol (2.04 g, 20.18 mmol) and K 2 CO 3 (5.6 g, 40.36 mmol).
  • Step 8 Preparation of (R)-1-(5-iodopyridin-2-yl)pyrrolidine-3-carbaldehyde [0308] To a solution of oxalyl chloride (2.42 g, 19.07 mmol) in DCM (30 mL) stirred at -78 °C was added DMSO (3 g, 38.14 mmol) slowly at -78 °C for 15 minutes. Then a solution of [(3R)-1-(5- iodopyridin-2-yl)pyrrolidin-3-yl]methanol (2.9 g, 9.54 mmol) in DCM (5 mL) was added slowly.
  • Step 10 Preparation of (R)-N-(4-(4-amino-1-(6-(3-(dimethoxymethyl)pyrrolidin-1-yl)pyridin-3-yl)-1H- pyrazolo[3,4-d]pyrimidin-3-yl)benzyl)-5-fluoro-2-methoxybenzamide
  • (R)-2-(3-(dimethoxymethyl)pyrrolidin-1-yl)-5-iodopyridine 300 mg, 0.86 mmol
  • DMSO 10 mL
  • N-(4-(4-amino-1H-pyrazolo[3,4-d]pyrimidin-3-yl)benzyl)-5- fluoro-2-methoxybenzamide 337 mg, 0.86 mmol
  • Na2CO3 182 mg, 1.72 mmol
  • copper(I) iodide 82 mg, 0.43 mmol
  • Step 11 Preparation of (R)-N-(4-(4-amino-1-(6-(3-formylpyrrolidin-1-yl)pyridin-3-yl)-1H-pyrazolo[3,4- d]pyrimidin-3-yl)benzyl)-5-fluoro-2-methoxybenzamide [0311] To solution of (R)-N-(4-(4-amino-1-(6-(3-(dimethoxymethyl)pyrrolidin-1-yl)pyridin-3- yl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)benzyl)-5-fluoro-2-methoxybenzamide (460 mg, 0.75 mmol) in anhydrous THF (2.5 mL) was added HCl (4 N, 2.5 ml in the dioxane).
  • Step 12 Preparation of N-(4-(4-amino-1-(6-((S)-3-((4-(2-((S)-2,6-dioxopiperidin-3-yl)-1-oxoiso indolin- 5-yl)piperazin-1-yl)methyl)pyrrolidin-1-yl)pyridin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)benzyl)-5- fluoro-2-methoxybenzamide [0312] To a solution of (R)-N-(4-(4-amino-1-(6-(3-formylpyrrolidin-1-yl)pyridin-3-yl)-1H- pyrazolo[3,4-d]pyrimidin-3-yl)benzyl)-5-fluoro-2-methoxybenzamide (300 mg, crude) in MeOH/DMF (12 mL, 2:1) stirred at room temperature was added (S)-3-
  • Step 2 Preparation of (S)-(1-(4-amino-2-fluorophenyl)pyrrolidin-3-yl)methanol
  • Pd/C 0.28 g, 10 % purity, 10.5 mmol
  • the reaction was stirred under H2 atmosphere at 1 atm for 16 hours at 25 °C.
  • the catalyst was filtered off and washed with MeOH.
  • the solution was concentrated in vacuum to afford the desired product (2.2 g, 99.6 %) as a brown oil.
  • Step 3 Preparation of (S)-(1-(2-fluoro-4-iodophenyl)pyrrolidin-3-yl)methanol [0315] To a solution of (S)-(1-(4-amino-2-fluorophenyl)pyrrolidin-3-yl)methanol (2.1 g, 9.98 mmol) in CH 3 CN (30 mL) was added con. HCl (2.5 mL), NaNO 2 (827 mg, 11.98 mmol, dissolved in 5 mL H2O) at 0 °C.
  • Step 4 Preparation of (S)-1-(2-fluoro-4-iodophenyl)pyrrolidine-3-carbaldehyde [0316] To a solution of (S)-(1-(2-fluoro-4-iodophenyl)pyrrolidin-3-yl)methanol (1.9 g, 5.9 mmol) in DCM (20 mL) was added Dess-Martin periodinane (3.75 g, 8.8 mmol). The reaction was stirred at 25 °C for 2 hours. The reaction was quenched with saturated Na2S2O3 solution then extracted with EA. The organic phase was washed with brine and dried over Na 2 SO 4 .
  • Step 5 Preparation of (S)-3-(dimethoxymethyl)-1-(2-fluoro-4-iodophenyl)pyrrolidine [0317] To a solution of (S)-1-(2-fluoro-4-iodophenyl)pyrrolidine-3-carbaldehyde (2.0 g, 80 % purity, 5.0 mmol) in MeOH (20 mL) was added acetyl chloride (1.04 g, 13.2 mmol) stirred under nitrogen at 0 °C. The reaction was stirred at 25 °C for 2 hours. The reaction was quenched with TEA and the solvent was removed in vacuum.
  • Step 7 Preparation of (S)-N-(4-(4-amino-1-(3-fluoro-4-(3-formylpyrrolidin-1-yl)phenyl)-1H-pyrazo lo[3,4-d]pyrimidin-3-yl)benzyl)-5-fluoro-2-methoxybenzamide [0319] To a solution of (S)-N-(4-(4-amino-1-(4-(3-(dimethoxymethyl)pyrrolidin-1-yl)-3- fluorophenyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)benzyl)-5-fluoro-2-methoxybenzamide (170 mg, 90 % purity, 0.24 mmol) in DCM (4 mL) was added HCl (4N in the dioxane, 4 mL) stirred under nitrogen at 25°C.
  • Step 8 Preparation of N-(4-(4-amino-1-(4-((R)-3-((4-(2-((S)-2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5- yl)piperazin-1-yl)methyl)pyrrolidin-1-yl)-3-fluorophenyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)benzyl)-5- fluoro-2-methoxybenzamide [0320] To a solution of (S)-3-(1-oxo-5-(piperazin-1-yl)isoindolin-2-yl)piperidine-2,6-dione (150 mg, 0.3 mmol) in MeOH/DMF/AcOH (5 mL, 2:1:0.02) was added (S)-N-(4-(4-amino-1-(3-fluoro-4- (3-formylpyrrolidin-1-y
  • Example 80 Preparation of N-(4-(4-amino-1-(4-((S)-3-((4-(2-((S)-2,6-dioxopiperidin-3-yl)-1- oxoisoindolin-5-yl)piperazin-1-yl)methyl)pyrrolidin-1-yl)-3-fluorophenyl)-1H-pyrazolo[3,4- d]pyrimidin-3-yl)benzyl)-5-fluoro-2-methoxybenzamide (Compound 96) Compound 96 was prepared analogously with the procedure described for compound 95. LC/MS: 896.6 [M+H] + .
  • Example 81 Preparation of (S)-N-(4-(4-amino-1-(6-(3-((4-(2-(2,6-dioxopiperidin-3-yl)-1- oxoisoindolin-5-yl)piperazin-1-yl)methyl)azetidin-1-yl)pyridin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin- 3-yl)benzyl)-5-fluoro-2-methoxybenzamide (Compound 97) Step 1: Preparation of (1-(5-iodopyridin-2-yl)azetidin-3-yl)methanol [0321] To a solution of 2-fluoro-5-iodopyridine (2.2 g, 9.86 mmol) in DMA (100 mL) stirred under argon at room temperature was added azetidin-3-ylmethanol (1.2 g, 9.86 mmol) and potassium carbonate
  • Step 3 Preparation of 2-(3-(dimethoxymethyl)azetidin-1-yl)-5-iodopyridine [0323] To a solution of 1-(5-iodopyridin-2-yl) azetidine-3-carbaldehyde (700 mg, 2.42 mmol) in MeOH (10 mL) stirred under argon at 0 °C was added acetyl chloride (381 mg, 4.859 mmol). The reaction mixture was stirred at room temperature for 2 hours. The reaction was quenched with TEA (1 mL).
  • Step 4 Preparation of N-(4-(4-amino-1-(6-(3-(dimethoxymethyl)azetidin-1-yl)pyridin-3-yl)-1H- pyrazolo[3,4-d]pyrimidin-3-yl)benzyl)-5-fluoro-2-methoxybenzamide [0324] To a solution of 2-[3-(dimethoxymethyl)azetidin-1-yl]-5-iodopyridine (200 mg, 0.59 mmol) in DMSO (13 mL) was added N-[(4- ⁇ 4-amino-1H-pyrazolo[3,4-d]pyrimidin-3-yl ⁇ phenyl)methyl]- 5-fluoro-2-methoxy
  • Step 5 Preparation of N-(4-(4-amino-1-(6-(3-formylazetidin-1-yl)pyridin-3-yl)-1H-pyrazolo[3,4- d]pyrimidin-3-yl)benzyl)-5-fluoro-2-methoxybenzamide
  • RAMOS (ATCC) cells were plated in 24-well plates at 8 ⁇ 10 5 cells/well in the RPMI growth medium containing 10% heat-inactivated FBS and 1x Penicillin Streptomycin, and then incubated at 37°C overnight. The following day, the test compound was administered to the cells by using 1000x compound stock solution prepared in DMSO at various concentrations. After administration of the compound, the cells were then incubated at 37°C for 6 hours. [0328] Upon completion, the cells were collected by centrifugation and lysed in Laemmli sample buffer (1x; VWR International).
  • Proteins in cell lysate were separated by SDS-PAGE and transferred to Odyssey nitrocellulose membranes (Licor) with iblot® dry blotting transfer system (ThermoFisher). Nonspecific binding was blocked by incubating membranes with Intercept Blocking Buffer (Licor) for 1 hour at room temperature with gentle shaking. The membranes were then incubated overnight at 4 °C with primary antibodies anti-BTK (Cell signaling, cat. #8547) and anti-GAPDH (Cell signaling, cat. #5179) diluted in Intercept Blocking Buffer containing 0.1% Tween 20.
  • Intercept Blocking Buffer containing 0.1% Tween 20.
  • FIG. 1 and Figure 2 illustrate the BTK degradative activity of exemplary compounds 13, 25, 34, 42, 48, 49, 51, 53, 54, 78, 93 and 96 of the present disclosure in a RAMOS cell line 6 hours after administration.
  • Table 3 summarizes the BTK degradative activity of exemplary compounds of the present disclosure in a RAMOS cell line 6 hours after administration.
  • the DC 50 values i.e., the concentration of test compound at which 50% of the target protein is degraded
  • a designation of “A” corresponds to a DC 50 value less than 10 nM.
  • a designation of “B” corresponds to a DC 50 value greater than or equal to 10 nM and less than 100 nM.
  • a designation of “C” corresponds to a DC 50 value greater than or equal to 100 nM.
  • REC-1 BTK C481S cell line The BTK gene in REC-1 cell line (ATCC) was edited by the CRISPR-Cas9 technology to create a C to S point mutation at residue 481 of BTK protein.
  • gRNA complex was prepared with Alt-R CRISPR-Cas9 tracrRNA and crRNA BTK C481S (5’- GUAGUUCAGGAGGCAGCCAU-3’) (IDT-Integrated DNA Technologies), and then BTK C481S ribonucleoprotein (RNP) complex was prepared with gRNA complex and Alt-R S.p. Cas9 Nuclease V3
  • C481S mutation of BTK was further validated by Sanger Sequencing using gDNA extracted from these cells.
  • Growth inhibitory activity of exemplary compounds of the present disclosure in a BTK-dependent REC-1 and REC-1 BTK C481S cell line [0332] REC-1 (ATCC) and REC-1 BTK C481S cells were plated in 96-well plates at 8,000 cells/well in 90 ul of RPMI growth medium containing 10% heat-inactivated FBS and 1x Penicillin Streptomycin, and then incubated at 37°C overnight. The following day, the test compound was administered to the cells by using 10x compound stock solution prepared in growth medium at various concentrations. After administration of the compound, cells were then incubated at 37°C for 6 days.
  • Table 4 summarizes the growth inhibitory activity of exemplary compounds of the present disclosure in a BTK-dependent REC-1 and REC1 BTK C481S cell line 6 days after administration.
  • the GI50 values i.e., the concentration of test compound at which 50% of cell growth are inhibited were calculated.
  • a designation of “A” corresponds to a DC 50 value less than 20 nM.
  • a designation of “B” corresponds to a DC 50 value greater than or equal to 20 nM and less than 200 nM.
  • a designation of “C” corresponds to a DC 50 value greater than or equal to 200 nM.
  • Table 4 154 The GI50 values (i.e., the concentration of test compound at which 50% of cell growth are inhibited) were calculated.
  • a designation of “A” corresponds to a DC 50 value less than 20 nM.
  • a designation of “B” corresponds to a DC 50 value greater than or equal to 20 nM and less than 200 nM.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PCT/US2022/014830 2021-02-03 2022-02-02 Substituted pyrrolopyrimidine and pyrazolopyrimidine as bruton's tyrosine kinase (btk) degraders Ceased WO2022169798A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
US18/263,656 US20240132502A1 (en) 2021-02-03 2022-02-02 Substituted pyrrolopyrimidine and pyrazolopyrimidine as bruton's tyrosine kinase (btk) degraders
KR1020237029298A KR20230142539A (ko) 2021-02-03 2022-02-02 브루톤 티로신 키나제(btk) 분해제로서의 치환된 피롤로피리미딘 및 피라졸로피리미딘
MX2023008865A MX2023008865A (es) 2021-02-03 2022-02-02 Pirrolopirimidina y pirazolopirimidina sustituidas como degradadores de tirosina cinasa de bruton (btk).
CA3209082A CA3209082A1 (en) 2021-02-03 2022-02-02 Substituted pyrrolopyrimidine and pyrazolopyrimidine as bruton's tyrosine kinase (btk) degraders
CN202280022626.5A CN117042769A (zh) 2021-02-03 2022-02-02 作为布鲁顿酪氨酸激酶(btk)降解剂的取代的吡咯并嘧啶和吡唑并嘧啶
JP2023546433A JP2024505558A (ja) 2021-02-03 2022-02-02 ブルトン型チロシンキナーゼ（ｂｔｋ）分解剤としての置換ピロロピリミジンおよびピラゾロピリミジン

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163145126P 2021-02-03 2021-02-03
US63/145,126 2021-02-03

Publications (2)

Publication Number Publication Date
WO2022169798A2 true WO2022169798A2 (en) 2022-08-11
WO2022169798A3 WO2022169798A3 (en) 2022-09-22

Family

ID=80447078

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2022/014830 Ceased WO2022169798A2 (en) 2021-02-03 2022-02-02 Substituted pyrrolopyrimidine and pyrazolopyrimidine as bruton's tyrosine kinase (btk) degraders

Country Status (11)

Country Link
US (2) US20240132502A1 (https=)
EP (2) EP4501327A3 (https=)
JP (1) JP2024505558A (https=)
KR (1) KR20230142539A (https=)
CN (1) CN117042769A (https=)
CA (1) CA3209082A1 (https=)
DK (1) DK4039688T3 (https=)
ES (1) ES3010513T3 (https=)
FI (1) FI4039688T3 (https=)
MX (1) MX2023008865A (https=)
WO (1) WO2022169798A2 (https=)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4211117A1 (en) * 2020-09-10 2023-07-19 Loxo Oncology, Inc. Processes and intermediates for the preparation of (s)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropane-2-yl)-1h-pyrazole-4-carboxamide
WO2023122481A3 (en) * 2021-12-20 2023-08-03 Sigma-Aldrich Co. Llc Chemical linkers
WO2024169871A1 (zh) * 2023-02-17 2024-08-22 江苏威凯尔医药科技有限公司 Btk抑制剂及其用途
WO2024244888A1 (zh) * 2023-05-26 2024-12-05 广东弘烨医药科技有限公司 9元杂芳基化合物、含其的药物组合物及其制备方法和应用
WO2026040951A1 (zh) * 2024-08-19 2026-02-26 深圳市塔吉瑞生物医药股份有限公司 靶向btk蛋白降解靶向嵌合体类化合物及其组合物及用途

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2024298923A1 (en) 2023-07-25 2026-01-22 Monte Rosa Therapeutics Ag Substituted piperidinediones for targeted protein degradation
CN120535526A (zh) * 2024-02-26 2025-08-26 中国药科大学 直接结合蛋白酶体的非泛素依赖型蛋白水解靶向嵌合体NuTAC及其应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5114946A (en) 1987-06-12 1992-05-19 American Cyanamid Company Transdermal delivery of pharmaceuticals
US4818541A (en) 1987-08-19 1989-04-04 Schering Corporation Transdermal delivery of enantiomers of phenylpropanolamine
CN105017256A (zh) * 2014-04-29 2015-11-04 浙江导明医药科技有限公司 多氟化合物作为布鲁顿酪氨酸激酶抑制剂
CN106146511A (zh) * 2015-04-03 2016-11-23 安润医药科技（苏州）有限公司 吡唑并嘧啶衍生物、制备方法、药物组合物及用途
JP7337502B2 (ja) * 2015-09-16 2023-09-04 ロクソ オンコロジー， インコーポレイテッド がんの治療のためのｂｔｋ阻害剤としてのピラゾロピリミジン誘導体
ES2965081T3 (es) * 2016-07-07 2024-04-11 Daewoong Pharmaceutical Co Ltd Derivados 4-aminopirazolo[3,4-d]pirimidinil-azabiciclo y composición farmacéutica que comprende dichos derivados
TW201811795A (zh) * 2016-08-24 2018-04-01 美商亞闊股份有限公司 胺基－吡咯并嘧啶酮化合物及其用途
EP3765026A4 (en) * 2018-03-10 2021-12-22 Yale University BTK PROTEOLYSIS MODULATORS AND METHODS FOR USE
WO2020023851A1 (en) * 2018-07-26 2020-01-30 Yale University Bifunctional substitued pyrimidines as modulators of fak proteolyse
CN113544130B (zh) * 2019-05-31 2024-01-09 西藏海思科制药有限公司 一种btk抑制剂环衍生物及其制备方法和药学上的应用
WO2020252397A1 (en) * 2019-06-12 2020-12-17 Baylor College Of Medicine Small molecule proteolysis-targeting chimeras and methods of use thereof
CN112812100B (zh) * 2019-11-18 2022-04-05 四川海思科制药有限公司 一种具有降解btk激酶的化合物及其制备方法和药学上的应用
CN112979656A (zh) * 2019-12-12 2021-06-18 上海美志医药科技有限公司 一类靶向降解btk蛋白的化合物

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4211117A1 (en) * 2020-09-10 2023-07-19 Loxo Oncology, Inc. Processes and intermediates for the preparation of (s)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropane-2-yl)-1h-pyrazole-4-carboxamide
WO2023122481A3 (en) * 2021-12-20 2023-08-03 Sigma-Aldrich Co. Llc Chemical linkers
WO2024169871A1 (zh) * 2023-02-17 2024-08-22 江苏威凯尔医药科技有限公司 Btk抑制剂及其用途
WO2024244888A1 (zh) * 2023-05-26 2024-12-05 广东弘烨医药科技有限公司 9元杂芳基化合物、含其的药物组合物及其制备方法和应用
WO2026040951A1 (zh) * 2024-08-19 2026-02-26 深圳市塔吉瑞生物医药股份有限公司 靶向btk蛋白降解靶向嵌合体类化合物及其组合物及用途

Also Published As

Publication number Publication date
CN117042769A (zh) 2023-11-10
US20220259207A1 (en) 2022-08-18
ES3010513T3 (en) 2025-04-03
EP4039688B1 (en) 2024-10-09
DK4039688T3 (da) 2025-01-02
EP4039688A3 (en) 2022-11-23
JP2024505558A (ja) 2024-02-06
EP4039688A2 (en) 2022-08-10
CA3209082A1 (en) 2022-08-11
MX2023008865A (es) 2023-08-31
FI4039688T3 (fi) 2024-12-19
EP4501327A3 (en) 2025-10-15
KR20230142539A (ko) 2023-10-11
US20240132502A1 (en) 2024-04-25
US11530222B2 (en) 2022-12-20
WO2022169798A3 (en) 2022-09-22
EP4501327A2 (en) 2025-02-05

Similar Documents

Publication Publication Date Title
EP4501327A2 (en) Substituted pyrrolopyrimidine and pyrazolopyrimidine as bruton s tyrosinekinase (btk) degraders
CA3124898C (en) Heterocyclic compound, intermediate, preparation method therefor and application thereof
WO2021252339A1 (en) Substituted purine-2,6-dione compounds as kras inhibitors
TWI804003B (zh) Tlr7/8拮抗劑及其用途
EP4626555A1 (en) Glutarimide-containing pan-kras-mutant degrader compounds and uses thereof
JP7125385B2 (ja) Ｔｌｒ７／８アンタゴニストおよびそれらの使用
US20240208909A1 (en) Substituted quinoline derivatives having sos1 inhibition activities and uses thereof
WO2021216770A1 (en) Substituted tetrahydroquinazoline compounds as kras inhibitors
CN112778276A (zh) 作为shp2抑制剂的化合物及其应用
AU2019326368B2 (en) Inhibitors of KEAP1-Nrf2 protein-protein interaction
WO2022081655A1 (en) Substituted dihydropyranopyrimidine compounds as kras inhibitors
EP3675839A1 (en) Novel compounds having estrogen receptor alpha degradation activity and uses thereof
US20240287076A1 (en) Compounds for targeting degradation of bruton's tyrosine kinase
WO2021061204A1 (en) Novel substituted quinoline-8-carbonitrile derivatives having androgen receptor degradation activity and uses thereof
TW202237597A (zh) 新型egfr降解劑
EP4034114A1 (en) Novel ureas having androgen receptor degradation activity and uses thereof
TW202122382A (zh) 乙內醯脲衍生物
JP7812861B2 (ja) サイクリン依存性キナーゼ７（ｃｄｋ７）阻害剤としての三環式ピリミジン
US20240190842A1 (en) Substituted quinolinone-8-carbonitrile derivatives having androgen degradation activity and uses thereof
EP4596544A1 (en) Ep300/cbp regulator, and preparation method therefor and use thereof
CA3054459A1 (en) Azetidine derivative
CN115066423B (zh) Pd-l1拮抗剂化合物
US20240132464A1 (en) Heterocyclic compounds as e3 ligase inhibitors
WO2026060424A1 (en) Akt degrader compounds and uses thereof
WO2026072966A2 (en) Pi3k degrader compounds and uses thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22750279

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 3209082

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: MX/A/2023/008865

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 18263656

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2023546433

Country of ref document: JP

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112023015119

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 20237029298

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 112023015119

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20230727

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 202280022626.5

Country of ref document: CN

122 Ep: pct application non-entry in european phase

Ref document number: 22750279

Country of ref document: EP

Kind code of ref document: A2